ikt-10q_20210630.htm

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001564590-21-044637.txt : 20210816 0001564590-21-044637.hdr.sgml : 20210816 20210816161602 ACCESSION NUMBER: 0001564590-21-044637 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 211178395 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 10-Q 1 ikt-10q_20210630.htm 10-Q ikt-10q_20210630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39676

INHIBIKASE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	26-3407249
( State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA	30339
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (678) 392-3419

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

IKT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 31, 2021, the registrant had 25,133,345 shares of common stock, $0.001 par value per share, outstanding.

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Condensed Financial Statements (Unaudited)	1
	Condensed Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020	1
	Condensed Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 (unaudited)	2
	Condensed Statements of Stockholders’ Equity (Deficit) for the Three and Six Months Ended June 30, 2021 and 2020 (unaudited)	3
	Condensed Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (unaudited)	4
	Notes to Unaudited Condensed Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20
PART II.	OTHER INFORMATION	21
Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	23
Signatures		24

PART I—FINANCIAL INFORMATION

Item 1. Condensed Financial Statements (Unaudited).

Inhibikase Therapeutics, Inc.

Condensed Balance Sheets

	June 30, 2021			December 31, 2020
	(unaudited)			(Note 3)
Assets
Current assets:
Cash	$	46,836,556		$	13,953,513
Grants receivable		586,581			—
Prepaid research and development		958,779			774,356
Prepaid expenses and other current assets		833,963			54,837
Total assets	$	49,215,879		$	14,782,706
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	897,226		$	1,720,680
Accrued expenses and other current liabilities		872,771			632,934
Deferred revenue		142,619			2,325,741
Notes payable		—			42,534
Total		1,912,616			4,721,889
Notes payable, net of current portion		248,911			276,461
Total liabilities		2,161,527			4,998,350
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2021, and December 31, 2020; 0 shares issued and outstanding at June 30, 2021, and December 31, 2020		—			—
Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 25,133,345 and 10,050,849 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively.		25,134			10,051
Additional paid-in capital		67,334,089			24,805,929
Accumulated deficit		(20,304,871	)		(15,031,624	)
Total		47,054,352			9,784,356
Total liabilities and stockholders' equity	$	49,215,879		$	14,782,706

See accompanying notes to condensed financial statements.

Inhibikase Therapeutics, Inc.

Condensed Statements of Operations

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Revenue:
Grant revenue	$	1,363,037		$	219,585		$	2,770,202		$	490,372
Total revenue		1,363,037			219,585			2,770,202			490,372
Costs and expenses:
Research and development		2,382,433			263,175			4,814,293			546,289
Selling, general and administrative		1,608,972			370,331			3,209,548			898,019
Total costs and expenses		3,991,405			633,506			8,023,841			1,444,308
Loss from operations		(2,628,368	)		(413,921	)		(5,253,639	)		(953,936	)
Interest expense		(7,811	)		(7,948	)		(19,608	)		(15,373	)
Net loss	$	(2,636,179	)	$	(421,869	)	$	(5,273,247	)	$	(969,309	)
Net loss per share – basic and diluted	$	(0.22	)	$	(0.05	)	$	(0.47	)	$	(0.12	)
Weighted-average number of common shares – basic and diluted		12,241,935			8,181,938			11,153,986			8,181,836

See accompanying notes to condensed financial statements.

Inhibikase Therapeutics, Inc.

Condensed Statements of Stockholders’ Equity (Deficit)

(Unaudited)

	Common Stock
	Shares		Amount		Additional Paid-In Capital			Accumulated Deficit			Total Stockholders’ Equity
Balance at December 31, 2020		10,050,849	$	10,051	$	24,805,929		$	(15,031,624	)	$	9,784,356
Stock-based compensation expense		—		—		591,124			—			591,124
Warrant expense		—		—		237,768			—			237,768
Issuance of common stock		9,000		9		60,382			—			60,391
Net loss		—		—		—			(2,637,068	)		(2,637,068	)
Balance at March 31, 2021		10,059,849	$	10,060	$	25,695,203		$	(17,668,692	)	$	8,036,571
Stock-based compensation expense		—		—		322,483			—			322,483
Warrant expense		—		—		239,415			—			239,415
Issuance of common stock, follow on offering		15,000,000		15,000		41,120,357			—			41,135,357
Issuance of common stock, stock options exercised		73,496		74		(43,369	)		—			(43,295	)
Net loss		—		—		—			(2,636,179	)		(2,636,179	)
Balance at June 30, 2021		25,133,345	$	25,134	$	67,334,089		$	(20,304,871	)	$	47,054,352

	Common Stock
	Shares		Amount		Additional Paid-In Capital		Accumulated Deficit			Total Stockholders’ Equity (Deficit)
Balance at December 31, 2019		8,180,937	$	8,181	$	7,685,533	$	(12,183,730	)	$	(4,490,016	)
Stock-based compensation expense		—		—		139,758		—			139,758
Warrent expense		—		—		190,993		—			190,993
Issuance of common stock		874		1		4,870		—			4,871
Net loss				—		—		(547,440	)		(547,440	)
Balance March 31, 2020		8,181,811	$	8,182	$	8,021,154	$	(12,731,170	)	$	(4,701,834	)
Stock-based compensation expense		—		—		139,759		—			139,759
Issuance of warrants		—		—		89,515		—			89,515
Conversion of notes		11,594		11		63,789		—			63,800
Net loss		—		—		—		(421,869	)		(421,869	)
Balance at June 30, 2020		8,193,405	$	8,193	$	8,314,217	$	(13,153,039	)	$	(4,830,629	)

See accompanying notes to condensed financial statements.

Inhibikase Therapeutics, Inc.

Condensed Statements of Cash Flows

(Unaudited)

	Six Months Ended June 30,
	2021			2020
Operating activities
Net loss	$	(5,273,247	)	$	(969,309	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		913,607			279,517
Non-cash consulting fees		60,391			75,000
Non-cash PPP loan forgiveness		(27,550	)		—
Warrant expense		477,183			280,509
Changes in operating assets and liabilities:
Grants receivable		(586,581	)		—
Prepaid expenses and other assets		(779,126	)		(5,640	)
Prepaid research and development		(184,423	)		—
Accounts payable		(837,705	)		(211,076	)
Accrued expenses and other current liabilities		239,837			209,149
Deferred revenue		(2,183,122	)		83,508
Net cash used in operating activities		(8,180,736	)		(258,342	)

Financing activities
Proceeds from notes payable		—			272,800
Proceeds from issuance of common stock		41,149,608			4,870
Deferred initial public offering costs		—			(30,000	)
Issuance of common stock from exercise of stock options		34,357			—
Payment of employee taxes in connection with stock option exercise		(77,652	)		—
Repayments of note payable		(42,534	)		—
Net cash provided by financing activities		41,063,779			247,670
Net increase (decrease) in cash		32,883,043			(10,672	)
Cash at beginning of period		13,953,513			18,457
Cash at end of period	$	46,836,556		$	7,785
Supplemental disclosures of cash flow information
Cash paid for interest	$	19,608		$	3,132
Non-cash financing activities
Notes payable settled with new notes payable	$	—		$	42,534
Notes payable settled with common stock	$	—		$	63,800
PPP loan forgiveness	$	27,550		$	—
Accrued deferred initial public offering costs	$	—		$	303,417

See accompanying notes to condensed financial statements.

Inhibikase Therapeutics, Inc.

Notes to Condensed Financial Statements

(Unaudited)

1.	Nature of Business

Inhibikase Therapeutics, Inc. (the “Company”, “we” or “our”) is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. In 2021, we commenced clinical development of IkT-148009, a small molecule Abelson Tyrosine Kinase inhibitor we believe can modify the course of Parkinson’s disease and its manifestation in the gastrointestinal tract, or GI. Results to date of our ongoing Phase 1 Single and Multiple Ascending Dose escalation study (SAD and MAD, respectively) in older and elderly healthy volunteers have revealed important insights into the metabolism of IkT-148009 in human subjects. Outcomes of this study have led to an acceleration of the clinical development program by more than 6 months. In July 2021, the U.S. Food and Drug Administration (“FDA”) agreed with the Company’s plan to initiate its Phase 1b study in Parkinson’s patients. We plan to initiate dosing in a Parkinson’s patient population in the third quarter of 2021. Clinical development of IkT-148009 for the GI complications in PD patients will cross-reference the Phase 1 study of IkT-148009 for the treatment of PD. Clinical development of the Company’s lead oncology asset, IkT-001Pro, is anticipated to begin shortly after submission of Company’s Investigational New Drug application for IkT-001Pro in the third quarter of 2021.

2.	Liquidity and Going Concern

The Company has recognized recurring losses. At June 30, 2021, the Company had working capital of $47,303,263, an accumulated deficit of $20,304,871, cash of $46,836,556, accounts payable and accrued expenses of $1,769,997 and notes payable of $248,911. The Company had active grants in the amount of $1,546,730, of which $772,420 remained available in accounts held by the U.S. Treasury as of April 30, 2021.

The future success of the Company is dependent on its ability to successfully obtain additional working capital, obtain regulatory approval for and successfully launch and commercialize its product candidates and to ultimately attain profitable operations. Historically, the Company has funded its operations primarily through cash received in connection with revenue from its various grant programs. In addition, in June 2021 and December 2020, the Company raised approximately $41.1 million and $14.6 million in working capital from its underwritten public offering (the “June 2021 Offering”) and its initial public offering (“IPO”), respectively.

The Company is subject to a variety of risks similar to other early-stage life science companies including, but not limited to, the successful development, regulatory approval, and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional working capital. The Company has incurred significant research and development expenses and general and administrative expenses related to its product candidate programs. The Company anticipates costs and expenses to increase in the future as the Company continues to develop its product candidates.

The Company may seek to fund its operations through additional public equity, private equity, or debt financings, as well as other sources. However, the Company may be unable to raise additional working capital, or if it is able to raise additional capital, it may be unable to do so on commercially favorable terms. The Company’s failure to raise capital or enter into such other arrangements if and when needed, would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to continue to develop its product candidates.

The Company estimates that its working capital at June 30, 2021 is sufficient to fund its normal operations into the first half of fiscal 2023.

The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

3.	Basis of Presentation and Significant Accounting Policies

Basis of Presentation of Interim Financial Statements

The accompanying unaudited condensed financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring

adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2020 balance sheet was derived from December 31, 2020 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2021. The condensed unaudited financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report filed on SEC Form 10-K.

These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The condensed financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

On August 21, 2020, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-1.14396 (1:1.14396) reverse stock split of its common stock, par value $.001 per share, effective August 24, 2020. All warrant, option, share, and per share information in the Company’s financial statements gives retroactive effect to the one-for-1.14396 reverse stock split that was effected on August 24, 2020.

The condensed financial statements have been prepared in conformity with US GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.

Use of Estimates

The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.

Concentrations of Credit Risk

For the three months ended June 30, 2021 and 2020, the Company derived more than 90% of its total revenue from a single source, the United States Government, in the form of federal research grants.

Revenue Recognition

The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s condensed statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received.

4.	Supplemental Balance Sheet Information

Accrued expenses and other current liabilities consist of the following:

	June 30, 2021		December 31, 2020
Accrued consulting	$	222,525	$	115,405
Accrued legal and professional fees		—		383,286
Accrued research and development		542,189		83,491
Accrued interest		653		1,673
Accrued bonuses		101,907		—
Accrued other		5,497		49,079
Total accrued expenses and other current liabilities	$	872,771	$	632,934

5.	Notes Payable

Notes payable outstanding were $248,911 and $318,995 at June 30, 2021 and December 31, 2020, respectively.

	June 30, 2021		December 31, 2020
Fifth Restated Note	$	—	$	42,534
PPP Note		—		27,550
CEO Restated Note		248,911		248,911
Total notes payable	$	248,911	$	318,995

Future principal payments on the notes payable as of June 30, 2021, are as follows:

Year ending December 31,
2021	$	—
2022		248,911
2023		—
2024		—
2025		—
Total notes payable	$	248,911

Revolving Demand Promissory Note

During 2019 and 2020, the Company entered into a series of promissory notes that were renegotiated and partially settled over 2019 and 2020.

On January 1, 2020, the Company issued a note (the “2020 Note”) in the face amount of $103,586 bearing 5.25% APR simple interest as settlement in full on the 2019 Note principal of $98,419 plus accrued interest of $5,167 that matured on January 1, 2020. The 2020 Note was scheduled to mature on January 1, 2021. Upon occurrence of certain conditions including the sale of a division of the Company or upon the date on which the Company closes on certain financings, the due date for some or all of the unpaid principal and accrued and unpaid interest may be accelerated. The Company assessed the terms and features of the 2020 Note and determined that none of the terms and features represented embedded derivatives that require bifurcation.

On June 30, 2020, the holder of the 2020 Note and the Company entered into an agreement to settle the 2020 Note early. As full consideration and settlement of the 2020 Note’s June 30, 2020 principal balance plus accrued and unpaid interest in the amount of $106,334, the Company issued a new promissory note to the holder in the amount of $42,534 (the “Fifth Restated Note”) with substantially similar terms as the 2020 Note. In addition, the holder subscribed for the purchase of 11,594 unregistered shares of the Company’s common stock at a subscription price of $63,800, or $5.50 per share. The issuance of shares under the subscription agreement and the issuance of the Fifth Restated Note satisfied the payoff of the 2020 Note without premium or discount. The balance of the Fifth Restated Note was $42,534 on December 31, 2020 and is included in Notes payable.

The Fifth Restated Note was scheduled to mature on the earlier of a significant transaction, including an initial public offering, sale of substantially all assets or change of control, or January 1, 2021. The Company consummated its IPO on December 28, 2020 and the principal balance of the Fifth Restated Note plus accrued and unpaid interest was settled in full in cash on January 1, 2021.

Note Payable to CEO

On February 5, 2020 (the “Issue Date”), the Company issued a note payable to its CEO (the “CEO Note”) in the face amount of $245,250 bearing 1.59% APR simple interest in exchange for cash. The net proceeds of $245,250 were used as working capital by the Company. The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note. If an event of default occurs and is continuing, the Company agrees to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan. The Company assessed the terms and features of the CEO Note and determined that none of the terms and features represented embedded derivatives that require bifurcation.

On June 13, 2020, the holder of the CEO Note and the Company entered into a restated agreement (the “CEO Restated Note”). The CEO Restated Note in the amount of $248,911 extends the stated maturity date of the CEO Note from the earlier of the sixth month following the (original) Issue Date or the date the Company has sufficient funds to repay the note to the earlier of the 30th month following the (original) Issue Date or the date the Company has sufficient funds to repay the CEO Restated Note. The Issue Date, February 5, 2020, is unchanged. In addition, the interest rate was reduced, effective as of the Issue Date, from 1.59% APR to 0.25%. The CEO Restated Note also changed the exercise price of the warrant from $4.87 to $4.81 per share in the case of any default. The other provisions of the CEO Restated Note are the same, in all material respects, to the CEO Note. The Company and its CEO have agreed that the CEO Restated Note will not be repaid for a minimum of 12 months following the closing of its IPO. The principal balance of the CEO Note was $248,911 at June 30, 2021 and at December 31, 2020 and is included on the condensed balance sheets in Notes payable, net of current portion.

The Payroll Protection Program Loan (the “PPP Loan”)

On May 4, 2020 the Company received $27,550 in loan proceeds as part of the Federal CARES Act Paycheck Protection Program (the “PPP Act” or “PPP”) with a 1% annual interest rate. Some or all of this loan qualified for forgiveness if the Company expended not less than 60% of the loan proceeds on qualified payroll costs. During the six months ended June 30, 2021, it was determined by the lender and by the Small Business Administration that the Company met the contractual conditions for forgiveness of the entire PPP Loan plus accrued interest and it was forgiven. The $27,550 principal balance of the PPP Loan at December 31, 2020 is included on the condensed balance sheet in Notes payable, net of current portion.

6.	Stockholders’ Deficit

Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding. A total of 5,186,570 and 4,318,357 shares of common stock were reserved for issuance upon the exercise of outstanding stock options and warrants as of June 30, 2021 and December 31, 2020, respectively.

Reverse Stock Split

On August 20, 2020, the board of directors adopted resolutions proposing that each 1.14396 shares of the Company’s issued and outstanding common stock, par value $0.001 per share, be automatically converted into one fully paid and non-assessable share of common stock, par value $0.001 (the “Reverse Stock Split”) with cash in lieu of fractional shares. On August 21, 2020, shareholders representing a majority of the issued and outstanding common stock approved the Reverse Stock Split. On August 21, 2020, the Company filed with the Delaware Secretary of State its Certificate of Amendment to its Certificate of Incorporation, effective as of August 24, 2020.

Share Issuances

In January 2020, an accredited investor subscribed for, and the Company issued, 874 shares of its stock in a private placement transaction at a per share price of $5.57. Net proceeds were approximately $4,870. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance.

During the six months ended June 30, 2021, an accredited investor subscribed for, and the Company issued, 9,000 shares of its stock in exchange for consulting services. The fair value of the stock was $60,391 based upon the closing price of the shares on the date of the transaction. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. The $60,391 fair value is a component of selling, general and administrative costs for the six months ended June 30, 2021.

During the six months ended June 30, 2020 the Company issued 73,496 shares of its stock in connection with the exercise of non-qualified stock options.

In connection with the June 2021 Offering, the Company issued and sold 15,000,000 fully paid non-assessable shares of its common stock at a public offering price of $3.00 per share. Proceeds from the June 2021 Offering were $41.1 million after deducting offering costs, underwriting discounts and commissions of approximately $3.9 million. The net proceeds are and will be used as working capital by the Company.

7.	Stock-Based Compensation

2020 Equity Incentive Plan

The Company’s 2020 Equity Incentive Plan (the “2020 Plan”) was established for granting stock incentive awards to directors, officers, employees and consultants to the Company.

Stock Options

During the six months ended June 30, 2021, the Company granted 68,628 options to its scientific advisory board members with a strike price of $6.82 per share, vesting immediately, with an aggregate grant date fair value of $259,674. No options were granted during the six months ended June 30, 2020.

On June 25, 2021, the Company granted a total of 90,708 options to members of its board of directors with a strike price of $2.92 per share, vesting one year from the date of the grant, with an aggregate grant date fair value of $160,000.

Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees:

	Six Months Ended June 30,
	2021		2020
Research and development	$	480,415	$	130,041
Selling, general and administrative		433,192		149,476
Total stock-based compensation expense	$	913,607	$	279,517

Warrants

Warrants Issued

On March 31, 2020, the Company issued a warrant to purchase up to 26,225 shares of its stock to one of its consultants in exchange for services. The warrant contains a strike price of $5.67 per share and has a seven-year contractual term. The warrant is classified within stockholders’ equity at its fair value and was treated as a standalone instrument. The fair value of the warrant was determined to be $101,478 utilizing the Black-Scholes-Merton option-pricing model at the time of issuance and is included in selling, general and administrative expenses for the six months ended June 30, 2020. There were no warrants issued during the six months ended June 30, 2021. The Company recognized $237,768 in warrant expense for the six months ended June 30, 2021 included in selling, general and administration expense.

In connection with the June 2021 Offering the Company issued and sold to its underwriters, a warrant to purchase up to 750,000 shares of its common stock for an aggregate purchase price of $100 pursuant to its written agreement with the underwriters. This warrant is exercisable beginning June 15, 2022 at an initial exercise price of $3.75 per share of common stock.

Warrants Exercised

No warrants were exercised for the three months ended June 30, 2021 and 2020.

9.	Net Loss Per Share

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:

	Six Months Ended June 30,
	2021			2020
Numerator:
Net loss	$	(5,273,247	)	$	(969,309	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		11,153,986			8,181,836
Net loss per share applicable to common stockholders – basic and diluted	$	(0.47	)	$	(0.12	)

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:

	Six Months Ended June 30,
	2021		2020
Options to purchase shares of stock		3,624,657		3,369,144
Warrants to purchase shares of stock		1,561,913		474,723
Total		5,186,570		3,843,867

10.	Income Taxes

During the six months ended June 30, 2021 and 2020, there was no provision for income taxes as the Company incurred losses during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company recorded a full valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized.

11.	Commitments and Contingencies

Impact of the COVID-19 Pandemic on Our Operations

The novel coronavirus SARS-Cov2, or COVID-19, pandemic is causing significant, industry-wide delays in clinical trials. There are multiple causes of these delays, including reluctance of patients to enroll or continue in trials for fear of exposure to COVID-19, local and regional shelter-in-place orders and regulations that discourage, hamper, or prohibit patient visits, healthcare providers and health systems shifting away from clinical trials toward the acute care of COVID-19 patients and the FDA and other regulators making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to the pandemic.

As a result of the COVID-19 pandemic, commencement of enrollment of our clinical trials may be delayed. In addition, after enrollment in these trials, if patients contract COVID-19 during participation in the Company’s trials or are subject to isolation or shelter-in-place restrictions, this may cause them to drop out of the Company’s trials, miss scheduled doses or follow-up visits or otherwise fail to follow trial protocols. If patients are unable to follow the trial protocols or if the Company’s trial results are otherwise affected by the consequences of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data from the Company’s trials may be compromised or not accepted by the FDA or other regulatory authorities, which could impact or delay a clinical development program. The Company anticipates that the COVID-19 pandemic may also impact manufacturing and distribution of materials necessary for the conductance of its clinical trials.

Although the Company did not experience a material impact on its operations during the six months ended June 30, 2021 and 2020, the Company notes the high level of difficulty in determining the future potential adverse financial impact and other effects of COVID-19 on the Company and its programs, given the rapid and dramatic evolution in the course and impact of the pandemic and the societal and governmental response to it.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability would include probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes to those statements included elsewhere in this Quarterly Report on From 10-Q (“Report”). This discussion and analysis and other parts of this Report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors.

All statements included or incorporated by reference in this Report, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates, approximations and projections about our industry and business, management’s beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” and similar expressions and variations or negatives of these words. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. These forward-looking statements speak only as of the date of this Report. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.

Overview

We are a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. In 2021, we commenced clinical development of IkT-148009, a small molecule Abelson Tyrosine Kinase inhibitor we believe can modify the course of Parkinson’s disease and its manifestation in the gastrointestinal tract, or GI. Results to date of our ongoing Phase 1 Single and Multiple Ascending Dose escalation study (SAD and MAD, respectively) in older and elderly healthy volunteers have revealed important insights into the metabolism of IkT-148009 in human subjects. We enrolled 56 subjects in the Phase 1 study. To date, 42 subjects have received IkT-148009. Results from the Phase 1 study have shown that IkT-148009 has a half-life of greater than 24 hours and just a 25 mg once daily oral dose in older and elderly healthy subjects in our Phase 1 study reached exposures that are consistent with the exposure to the drug that resulted in therapeutic efficacy in animal models of progressive Parkinson’s disease. This has led to an acceleration of the clinical development program by more than 6 months. Following agreements with the FDA, we will initiate dosing in a Parkinson’s patient population as part of the Phase 1 MAD study in 3Q21. Clinical development of IkT-148009 for the GI complications in PD patients will cross-reference the Phase 1 Study of IkT-148009 for the treatment of PD. In support of our clinical development program, we have now completed 3 months of our chronic toxicology program of IkT-148009 in both rats and monkeys. These toxicology studies will continue for 3 additional months in rats and 6 additional months in monkeys. We have also advanced clinical batch manufacturing and pill formulation for our platform prodrug technology involving IkT-001Pro.

Our programs utilize small molecule, oral protein kinase inhibitors to treat PD and its GI complications. We have shown in animal models of progressive disease that IkT-148009 is a brain penetrant Abelson tyrosine kinase, or c-Abl, inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. The ability to halt progression and restore function was shown in animal models of progressive disease that mimic the rate of disease progression and the extent of functional loss in the brain and/or the GI tract as found in patients with PD. We believe our therapeutic approach is disease-modifying. Our understanding of how and why PD progresses has led us to believe that functional loss in Parkinson’s patients may be at least partially reversed. Based on the measurements in animal models, we believe patients treated with IkT-148009 may have their disease progression slowed or halted, we may see a progressive reduction in the need for symptomatic or supportive therapy and/or we may ultimately eliminate the need for symptomatic therapy. However, it is unknown whether the disease modification seen in the animal models will occur in the human disease following treatment with IkT-148009.

In our opinion, the multi-decade failures in the treatment of neurodegenerative diseases such as PD result from a lack of understanding of the biochemistry of the disease processes involved. Neurodegeneration is marked by a progressive degeneration and loss of function of neurons which send and receive signals to and from the brain. Historically, the cause of a neurodegenerative disease was thought to be a “plaque” made up of a misfolded and/or aggregated protein(s). Therapeutic approaches, therefore, sought to remove “plaque” from the brain. A “plaque”-focused treatment strategy has failed to alter the course of Parkinson’s disease in two Phase 2 trials that reported results in 2020 and 2021. We believe we are different. We identified the proteins that become

dysfunctional in a disease pathway and sought to understand how a dysfunctional protein causes disease. We believe our approach to PD and other neurological diseases has identified the underlying cause of disease and led to an understanding of how individual proteins are linked together to define the disease process. Using this strategy, we believe we have discovered at least one enzyme that plays a pivotal role in the disease process for PD, the Abelson Tyrosin Kinase c-Abl. We have developed novel protein kinase inhibitors against c-Abl, which we believe can alter the disease course for PD. c-Abl chemically modifies one of the “plaque” proteins in PD, known as alpha-synuclein. Chemical modification creates what we believe to be the true toxic entity of the disease. Treatment with IkT-148009 may prevent chemical modification and, at least in animal models of progressive disease, leads to clearance of the toxic form of alpha-synuclein from the affected neurons.

In addition to programs in PD, our platform drug discovery and delivery technologies have identified additional opportunities, including a potential treatment for bacterial or viral infections in the brain using a single agent at fixed dose, and an oncology opportunity in stable-phase Chronic Myelogenous Leukemia, or CML. Our product for CML, IkT-001Pro, is a prodrug of the anticancer agent Imatinib. A prodrug is a compound that, after administration, is metabolized by the body into a pharmacologically active drug. Imatinib is an FDA designated Orphan Drug and is the standard-of-care treatment for stable-phase CML. In the United States, orphan drug designation entitles a party to incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. We intend to submit an IND to initiate clinical development for IkT-001Pro for the treatment of CML in the third quarter of 2021. Subject to future FDA agreements related to the clinical protocol design and execution of the clinical development program and additional funding, we believe that clinical development of IkT-001Pro could possibly be completed in 2022. We intend to submit a new drug application, or NDA, for IkT-001Pro pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which specifies the requirements for approval. This pathway would allow us to rely, in part, on data in the public domain or the FDA’s prior conclusions regarding the safety and effectiveness of an approved compound. Consistent with FDA guidance on the 505(b)(2) pathway, we will seek input from the FDA as to what should be included in the application prior to submission of the 505(b)(2) application. Pursuit of this oncology opportunity will seek to validate the pharmacology advantage of our prodrug technology in a well understood patient population with an approved drug substance. If we are able to validate IkT-001Pro in oncology, we will evaluate whether the pharmacology advantages we discover about IkT-001Pro could be applied to novel drug substances, such as IkT-148009.

We believe we are one of the pioneers of the application of protein kinase inhibitors to non-oncology indications, including neurodegeneration and infectious diseases, as well as their more traditional role in the treatment of cancer. As of the date of this Report, more than $20 million of the Company’s total funding has been received from Private, State and Federal granting agencies, including the National Institutes of Health, the Department of Defense and the Michael J. Fox Foundation, with the approximately $55.7 million raised from public offerings of our common stock. Private, State and Federal granting agencies use extensive scientific peer review in deciding which projects to fund that could impact human disease. We believe our ability to advance the Company on the basis of scientific peer review reflects the potential our scientific peers see for the possible success of our therapeutic programs.

In the ensuing 12 months, the Company anticipates reporting the full outcomes of its completed Phase 1 study of IkT-148009 in older and elderly healthy subjects, completing the ongoing chronic toxicology studies in rats and monkeys for IkT-148009 to enable chronic drug administration in Parkinson’s patients, completing a Phase 1b extension study of IkT-148009 in Parkinson’s patients and initiating its Phase 2 efficacy study in Parkinson’s patients. Advancement of IkT-148009 into Phase 1b was approved by the FDA July 22, 2021; advancement to proceed with the Phase 2 programs with IkT-148009 is subject to agreement on the protocol to be proposed for these trials. We further intend to advance IkT-001Pro through clinical development, possibly completing clinical development in 2022.

Our Programs

Our portfolio is focused on developing protein kinase inhibitors to treat PD in the brain and GI tract that arise from dysfunctional alpha-synuclein in PD patients. Using IkT-148009, we intend to clinically evaluate the impact of c-Abl inhibition on newly diagnosed PD patients, patients early in the course of PD, and PD patients with GI complications. We are pursuing clinical development using a sequential Phase 1/ Phase 2 development approach, with the details of the Phase 2 studies subject to agreements with the FDA regarding trial design and the outcome of the Phase 1 clinical trial. The Phase 1/Phase 2 development program, subject to FDA approval, would be followed with one or more Phase 3 clinical trials that we believe could lead to completion of the clinical development program in 2023 or 2024. IkT-148009 is intended to treat PD in treatment-naïve and early-stage PD patients, along with GI complications such as difficulty in swallowing, or dysphagia, and for treatment of neurogenic constipation.

active drug. Imatinib is an FDA designated Orphan Drug and is the standard-of-care treatment for stable-phase CML. In the United States, Orphan Drug designation entitles a party to incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. We remain on track to submit an IND to initiate clinical development for IkT-001Pro in the third quarter of 2021. Subject to future FDA agreements related to the clinical protocol design and execution of the clinical development program and additional funding, we believe that clinical development of IkT-001Pro could possibly be completed in 2022. We intend to submit a new drug application, or NDA, for IkT-001Pro pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which specifies the requirements for approval. This pathway would allow us to rely, in part, on data in the public domain or the FDA’s prior conclusions regarding the safety and effectiveness of an approved compound. Consistent with FDA guidance on the 505(b)(2) pathway, we will seek input from the FDA as to what should be included in the application prior to submission of the 505(b)(2) application. Pursuit of this oncology opportunity will seek to validate the pharmacology advantage of our prodrug technology in a well understood patient population with an approved drug substance. If we are able to validate IkT-001Pro in oncology, we will evaluate whether the pharmacology advantages we discover about IkT-001Pro could be applied to novel drug substances, such as IkT-148009.

Additional research programs will seek to develop medications for other alpha-synuclein-related diseases, specifically Dementia with Lewy Body, or DLB, and Multiple System Atrophy, or MSA, as well as our programs in anti-infectives that target host-factors to block viral or bacterial infections in the brain with a single agent at fixed dose. Our first application intends to treat infectious disease by suppressing John Cunningham virus, or JCV, virus infection, the cause of Progressive Multifocal Leukoencephalopathy, or PML.

Components of Operating Results

Operating Expenses

Research and Development

Research and development activities account for a significant portion of our operating expenses. Research and development expenses accounted for 26% and 37% of our operating expenses for the years ended December 31, 2020 and 2019, respectively. We record research and development expenses as incurred. Research and development expenses incurred by us for the discovery and development of our product candidates and prodrug technologies include:

•

external research and development expenses, including: expenses incurred under arrangements with third parties, such as CROs, preclinical testing organizations, clinical testing organizations, CMOs, academic and non-profit institutions and consultants;

•

fees related to our license and collaboration agreements;

•

personnel related expenses, including salaries, benefits and non-cash stock-based compensation expense; and

•

other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.

A portion of our research and development expenses are direct external expenses, which we track on a program-specific basis from inception of the program.

Program expenses include expenses associated with our most advanced product candidates and the discovery and development of compounds that are potential future candidates. We also track external expenses associated with our third-party research and development efforts. All external costs are tracked by therapeutic indication. We do not track personnel or other operating expenses incurred for our research and development programs on a program-specific basis. These expenses primarily relate to salaries and benefits and stock-based compensation and office consumables.

At this time, we can only estimate the nature, timing and costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:

•

our ability to add and retain key research and development personnel and other key employees;

•

our ability to successfully file investigational new drug (“IND”) and new drug applications (“NDA”) with the FDA;

•

our ability to conduct and commence trials;

•

our ability to establish an appropriate safety profile with IND-enabling toxicology studies;

•

our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;

•

our successful enrollment in and completion of our current and future clinical trials;

•

the costs associated with the development of any additional product candidates we identify in-house or acquire through collaborations;

•

our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our molecules;

•

our ability to establish agreements with third-party manufacturers for clinical supply for any future clinical trials and commercial manufacturing, if our product candidates are approved;

•

the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;

•

our ability to obtain and maintain patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates if and when approved;

•

our receipt of marketing approvals from applicable regulatory authorities;

•

the impact of the outbreak of the novel coronavirus disease, COVID-19, pandemic which has had an adverse impact on our business, including our preclinical studies and clinical trials;

•

our ability to commercialize products, if and when approved, whether alone or in collaboration with others; and

•

the continued acceptable safety profiles of the product candidates following approval.

A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. We expect our research and development expenses to increase for the next several years as we continue to implement our business strategy, advance our current programs, expand our research and development efforts, seek regulatory approvals for any product candidates that successfully complete clinical trials, access and develop additional product candidates and incur expenses associated with hiring additional personnel to support our research and development efforts. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.

Selling, General and Administrative

Selling, general and administrative expenses include personnel related expenses, such as salaries, benefits, travel and non-cash stock-based compensation expense, expenses for outside professional services and allocated expenses. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expenses related to our offices in Cambridge, Massachusetts and Atlanta, Georgia not otherwise included in research and development expenses.

We expect to incur additional expenses as compared to when we were a private company, including expenses related to compliance with the rules and regulations of the SEC and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase our administrative headcount when operating as a public company and as we advance our product candidates through clinical development, which will also likely require us to increase our selling, general and administrative expenses.

Results of Operations

Comparison of the Three Months Ended June 30, 2021 and 2020

The following table sets forth the significant components of our results of operations:

	For the Three Months Ended June 30,						Change
	2021			2020			($)			(%)
	(unaudited)
Grant revenue	$	1,363,037		$	219,585		$	1,143,452			520.7
Research and development		(2,382,433	)		(263,175	)		(2,119,258	)		805.3
Selling, general and administrative		(1,608,972	)		(370,331	)		(1,238,641	)		334.5
Loss from operations		(2,628,368	)		(413,921	)		(2,214,447	)		(535.0	)
Interest expense, net		(7,811	)		(7,948	)		137			(1.7	)
Net loss	$	(2,636,179	)	$	(421,869	)	$	(2,214,310	)		(524.9	)

Grant Revenue

Grant revenue for the three months ended June 30, 2021, increased by $1,143,452 or 521% to $1,363,037 from $219,585 in the prior year comparable period. The increase was driven by increased grant research activity during 2021 compared to 2020. During 2020, the Company’s focus was shifted toward advancing its Phase I clinical trial which did not result in grant revenue. The Company is utilizing its increased resources in 2021 to carry on its Phase I clinical trials in addition to its grant research activity.

Research and Development

Research and development expenses increased by $2,119,258 or 805% to $2,382,433 from $263,175 in the prior year comparable period. The increase was driven by a $1.0 million increase in grant related research expenditures and a $1.1 million increase in non-grant related research. The non-grant related research was expended primarily in connection with the Company’s Phase I PD clinical trial.

Selling, General and Administrative

Selling, general and administrative expenses increased by $1,238,641 or 335% to $1,608,972 from $370,331 in the prior year comparable period. The increase was primarily the result of increased non-cash stock compensation expense of $0.1 million, increased director and officer’s liability insurance of $0.3 million related to the Company’s IPO in December 2020, increased legal fees, board fees, investor relation and consulting fees of $0.3 million relating to operating as a public company registrant since December 2020 and a net increase of $0.5 million for other normal operating expenses.

Interest Expense

Interest expense decreased by $137 or 2% to $7,811 from $7,948 in the prior year comparable period. The increase was driven by financing of insurance premiums during the three months ended June 30, 2021. The Company experienced normal but significant increases in insurance premiums during the first three months of 2021 after its December 31, 2020 IPO. In the prior year, comparable period insurance premiums were not financed.

Comparison of the Six Months Ended June 30, 2021 and 2020

The following table sets forth the significant components of our results of operations:

	For the Six Months Ended June 30,						Change
	2021			2020			($)			(%)
	(unaudited)
Grant revenue	$	2,770,202		$	490,372		$	2,279,830			464.9
Research and development		(4,814,293	)		(546,289	)		(4,268,004	)		781.3
Selling, general and administrative		(3,209,548	)		(898,019	)		(2,311,529	)		257.4
Loss from operations		(5,253,639	)		(953,936	)		(4,299,703	)		450.7
Interest expense, net		(19,608	)		(15,373	)		(4,235	)		27.5
Net loss	$	(5,273,247	)	$	(969,309	)	$	(4,303,938	)		444.0

Grant Revenue

Grant revenue for the six months ended June 30, 2021, increased by $2,279,830 or 465% to $2,770,202 from $490,372 in the prior year comparable period. The increase was driven by increased grant research activity during 2021 compared to 2020. During 2020, the Company’s focus was shifted toward advancing its Phase I clinical trial which did not result in grant revenue. The Company is utilizing its increased resources in 2021 to carry on its Phase I clinical trial in addition to its grant research activity.

Research and Development

Research and development expenses increased by $4,268,004 or 781% to $4,814,293 from $546,289 in the prior year comparable period. The increase was driven by a $2.1 million increase in grant related research expenditures and a $2.1 million increase in non-grant related research. The non-grant related research was expended primarily in connection with the Company’s Phase I PD clinical trial.

Selling, General and Administrative

Selling, general and administrative expenses increased by $2,311,529 or 257% to $3,209,548 from $898,019 in the prior year comparable period. The increase was primarily the result of increased non-cash stock compensation expense of $0.5 million, increased director and officer’s liability insurance of $0.7 million related to the Company’s initial public offering in December 2020, increased legal fees, board fees, investor relation and consulting fees of $0.6 million relating to operating as a public company registrant since December 2020 and a net increase of $0.5 million for other normal operating expenses.

Interest Expense

Interest expense increased by $4,235 or 28% to $19,608 from $15,373 in the prior year comparable period. The increase was driven by financing of insurance premiums during the six months ended June 30, 2021. The Company experienced normal but significant increases in insurance premiums during the first six months of 2021 after its December 31, 2020, initial public offering. In the prior year comparable period insurance premiums were not financed.

Liquidity and Capital Resources

Sources of Liquidity

From our inception through June 30, 2021, we have funded our operations primarily through private, state and federal contracts and grants. From our inception through June 30, 2021, we generated aggregate cash proceeds of approximately $20.4 million from private, state and federal contracts and grants. In addition, in June 2021 and December 2020, the Company raised approximately $41.1 million and $14.6 million in working capital from its June 2021 Offering and its IPO, respectively.

At June 30, 2021, the Company had working capital of $47,303,263, an accumulated deficit of $20,304,871, cash of $46,836,556, and accounts payable and accrued expenses of $1,769,997 The Company had active grants in the amount of $1,546,730, of which $772,420 remained available in accounts held by the U.S. Treasury as of April 30, 2021.

Future Funding Requirements

To date, we have not generated any revenue from the sale of commercial products. We do not expect to generate any significant revenue from product sales unless and until we obtain regulatory approval of and successfully commercialize any of our product

candidates and we do not know when, or if, this will occur. We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any future approved products. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover, following the completion of the December 2020 IPO, we are incurring additional costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection with our continuing operations beyond 2022.

Until we can generate a sufficient amount of revenue from the commercialization of our product candidates, if ever, we expect to finance our incremental cash needs through a combination of equity offerings, debt financings, working capital lines of credit, grant funding and potential licenses and collaboration agreements. Additional working capital may not be available on commercially reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, reduce or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.

Since our inception, we have incurred significant losses and negative cash flows from operations. We have an accumulated deficit of $20,304,871 at June 30, 2021. We expect to incur substantial additional losses in the future as we conduct and expand our research and development activities.

We may seek to fund our operations through public equity or private equity or debt financings, as well as other sources. However, we may be unable to raise additional working capital, or if we are able to raise additional working capital, we may be unable to do so on commercially favorable terms. Our failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on our business, results of operations and financial condition and our ability to continue to develop our product candidates.

The Company had working capital of $47,303,263 at June 30, 2021 and active grants in the amount of $1,546,730, of which $772,420 remained available in accounts held by the U.S. Treasury as of April 30, 2021. The Company estimates that its working capital at June 30, 2021 is sufficient to funds it normal operations into the first half of fiscal 2023.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

The expected use of the net proceeds from our June 2021 Offering and December 2020 IPO represents our intentions based upon our current plans and business conditions. However, we have based these estimates on assumptions that may prove to be wrong, and we could deplete our working capital sooner than planned.

The timing and amount of our operating expenditures will depend largely on:

•

the timing and progress of preclinical and clinical development activities;

•

the number and scope of preclinical and clinical programs we decide to pursue;

•

possible delays or interruptions to preclinical studies, clinical trials, our receipt of services from our third-party service providers on whom we rely, or our supply chain due to the COVID-19 pandemic;

•

the progress of the development efforts of third parties with whom we have entered into license and collaboration agreements;

•

our ability to maintain our current research and development programs and to establish new research and development, license or collaboration arrangements;

•

our ability and success in securing manufacturing relationships with third parties or, in the future, in establishing and operating a manufacturing facility;

•

the costs involved in prosecuting, defending and enforcing patent claims and other intellectual property claims;

•

the cost and timing of regulatory approvals;

•

our efforts to enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates; and

•

the costs and ongoing investments to in-license and/or acquire additional technologies.

A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.

Cash Flows

The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below:

	Six Months Ended June 30,
	2021			2020
Net cash used in operating activities	$	(8,180,736	)	$	(258,342	)

Net cash provided by financing activities		41,063,779			247,670
Net increase (decrease) in cash	$	32,883,043		$	(10,672	)

Net Cash Flows Used in Operating Activities

Net cash flows used in operating activities for the six months ended June 30, 2021, totaled $8,180,736, and consisted primarily of a net loss of $5,273,247 adjusted for non-cash stock compensation of $913,607, non-cash warrant expense of $477,183, non-cash consulting fees of $60,391, non-cash PPP Loan forgiveness of $27,550, a decrease of $184,423 in prepaid research and development, an increase in prepaid expenses and other assets of $779,126, a decrease in accrued expenses and other current liabilities of $239,837, a decrease in accounts payable of $837,705 and a decrease in deferred revenue of $2,183,122 and an increase in grants receivable of $332,774.

Net cash flows used in operating activities for the six months ended June 30, 2020, totaled $258,342, and consisted primarily of a net loss of $969,309 adjusted for non-cash stock compensation of $279,517, non-cash warrant expense of $280,509, non-cash consulting fees of $75,000, a decrease in prepaid expenses of $5,640, a decrease in accounts payable of $211,076, an increase in accrued expenses of $209,149, and an increase in deferred revenue of $83,508.

Cash Provided by Financing Activities

Net cash flows provided by financing activities for the six months ended June 30, 2021, totaled $41,063,779, which primarily consisted of cash flows from capital raise of $41,149,608.

Net cash flows provided by financing activities for the six months ended June 30, 2020, totaled $247,670, which consisted of proceeds of $245,250 from the issuance of a note payable and $4,870 from the issuance of common stock.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements.

Contractual Obligations and Commitments

In June 2018, the Company entered into a one-year, non-cancelable operating lease for space in Boston, Massachusetts. The total lease obligation was $54,000, payable in 12 equal monthly installments commencing August 1, 2018. Since the end of the one-year initial term on July 31, 2019, the lease continues on a month-to-month basis.

Critical Accounting Policies and Significant Judgments and Estimates

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or US GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred

during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described in more detail in the notes to our financial statements included elsewhere in this Report, we believe that the following accounting policies are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

Research and Development Expenses

We record research and development expenses to operations as incurred. Research and development expenses represent costs incurred by us for the discovery and development of our product candidates and the development of our RAMP™ drug discovery program and prodrug technologies and include: employee-related expenses, such as salaries, benefits, travel and non-cash stock-based compensation expense; external research and development expenses incurred under arrangements with third parties, such as CROs, preclinical testing organizations, clinical testing organizations, CMOs, academic and non-profit institutions and consultants; costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use; license fees; and other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.

As part of the process of preparing financial statements, we are required to estimate and accrue expenses. A portion of our research and development expenses are external costs, which we track on a program-specific basis. We record the estimated expenses of research and development activities conducted by third-party service providers as they are incurred and provided within research and development expense in the statements of operations. These services include the conduct of preclinical studies and consulting services. These costs are a significant component of our research and development expenses.

Costs for research and development activities are recognized based on costs incurred. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from external clinical research organizations and other third-party service providers. Due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical trials and other research activities.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide disclosure regarding quantitative and qualitative market risk.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this report. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2021.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the six months ended June 30, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Not applicable as we are a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In May 2021, the Company issued 73,496 shares of its common stock in connection with the exercise of non-qualified stock options with a strike price of $0.38 per share. All such securities were issued without registration under the Securities Act of 1933, as amended, in reliance upon the exemption afforded by Section 4(a)(2) of that Act.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

			Incorporated by Reference to SEC Filing
Exhibit No.	Filed Exhibit Description	Form	Exhibit No.	File No.	Date Filed
3.1	Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc., as most recently amended and restated effective Wednesday, December 23, 2020.	8-K	3.1	001-39676	12/29/2020
3.2	Amended and Restated Bylaws of Inhibikase Therapeutics, Inc., as most recently amended and restated effective Wednesday, December 28, 2020.	8-K	3.2	001-39676	12/29/2020
10.1	Underwriting Agreement dated June 15, 2021 by and between Inhibikase Therapeutics, Inc. and ThinkEquity, a division of Fordham Financial Management, Inc., as representative of the underwriters listed on Schedule 1 thereto.	8-K	1.1	001-39676	6/16/2021
10.2	Form of Representative’s Warrant Agreement	8-K	4.2	001-39676	6/16/2021
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

*	Filed herewith.

**	Furnished herewith.

Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Inhibikase Therapeutics, Inc.

Date: August 16, 2021	By:	/s/ MILTON H. WERNER, Ph.D.
		Milton H. Werner, Ph.D.
		Chief Executive Officer (Principal Executive Officer)

Date: August 16, 2021	By:	/s/ JOSEPH FRATTAROLI
		Joseph Frattaroli
		Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 ikt-ex311_6.htm EX-31.1 ikt-ex311_6.htm

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Milton H. Werner, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Inhibikase Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Milton H. Werner

Milton H. Werner, Ph.D.

President and Chief Executive Officer

(Principal Executive Officer)

Date: August 16, 2021

EX-31.2 3 ikt-ex312_7.htm EX-31.2 ikt-ex312_7.htm

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joseph Frattaroli, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Inhibikase Therapeutics, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Joseph Frattaroli

Joseph Frattaroli

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

Date: August 16, 2021

EX-32.1 4 ikt-ex321_9.htm EX-32.1 ikt-ex321_9.htm

EXHIBIT 32.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Inhibikase Therapeutics, Inc. (the “Company”) for the period ended June 30, 2021 (the “Report”), the undersigned hereby certifies in his capacity as President and Chief Executive Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 16, 2021	By:	/s/ Milton H. Werner
		Milton H. Werner, Ph.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ikt-ex322_8.htm EX-32.2 ikt-ex322_8.htm

EXHIBIT 32.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Inhibikase Therapeutics, Inc. (the “Company”) for the period ended June 30, 2021 (the “Report”), the undersigned hereby certifies in his capacity as Chief Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 16, 2021	By:	/s/ Joseph Frattaroli
		Joseph Frattaroli
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

EX-101.SCH 6 ikt-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Statements of Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Nature of Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Liquidity and Going Concern link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Basis of Presentation and Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Supplemental Balance Sheet Information link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Notes Payable link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Stockholders' Deficit link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Warrants link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Supplemental Balance Sheet Information (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Notes Payable (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Liquidity and Going Concern - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Notes Payable - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Notes Payable - Summary of Notes Payable Outstanding (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Notes Payable - Summary of Future Principal Payments on Notes Payable (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Stockholders' Deficit - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Stock-based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Warrants - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 ikt-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ikt-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ikt-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Shell Company Entity Shell Company Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Current Reporting Status Entity Current Reporting Status Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash Cash Grants receivable Grants Receivable Current Prepaid research and development Prepaid Expense Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses and other current liabilities Accrued Liabilities Current Deferred revenue Contract With Customer Liability Current Notes payable Notes Payable Current Total Liabilities Current Notes payable, net of current portion Long Term Notes Payable Total liabilities Liabilities Commitments and contingencies (see Note 11) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2021, and December 31, 2020; 0 shares issued and outstanding at June 30, 2021, and December 31, 2020 Preferred Stock Value Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 25,133,345 and 10,050,849 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively. Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Revenue: Disaggregation Of Revenue [Abstract] Total revenue Revenue From Contract With Customer Excluding Assessed Tax Revenue from Contract with Customer, Product and Service [Extensible List] Revenue From Contract With Customer Product And Service Extensible List Costs and expenses: Operating Costs And Expenses [Abstract] Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total costs and expenses Costs And Expenses Loss from operations Operating Income Loss Interest expense Interest Expense Net loss Net Income Loss Net loss per share – basic and diluted Earnings Per Share Basic And Diluted Weighted-average number of common shares – basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] June 2021 Offering Over Allotment Option [Member] Statement [Line Items] Statement [Line Items] Beginning balance Beginning balance, Shares Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Warrant expense/ Issuance of warrants Fair Value Adjustment Of Warrants Issuance of common stock Stock Issued During Period Value New Issues Issuance of common stock, Shares Stock Issued During Period Shares New Issues Issuance of common stock, stock options exercised Stock Issued During Period Value Stock Options Exercised Issuance of common stock, stock options exercised, Shares Stock Issued During Period Shares Stock Options Exercised Conversion of notes Stock Issued During Period Value Conversion Of Units Conversion of notes, Shares Stock Issued During Period Shares Conversion Of Units Net loss Ending balance Ending balance, Shares Non-cash consulting fees. Non-cash PPP loan forgiveness. Increase (decrease) in prepaid research and development. Notes payable settled with common stock in non-cash financing activities. PPP loan forgiveness. Accrued deferred initial public offering costs. Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation expense Share Based Compensation Non-cash consulting fees Non Cash Consulting Fees Non-cash PPP loan forgiveness Non Cash P P P Loan Forgiveness Warrant expense Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Grants receivable Increase Decrease In Accounts Receivable Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid research and development Increase Decrease In Prepaid Research And Development Accounts payable Increase Decrease In Accounts Payable Accrued expenses and other current liabilities Increase Decrease In Other Accounts Payable And Accrued Liabilities Deferred revenue Increase Decrease In Deferred Revenue Net cash used in operating activities Net Cash Provided By Used In Operating Activities Financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from notes payable Proceeds From Notes Payable Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Deferred initial public offering costs Payments For Repurchase Of Initial Public Offering Issuance of common stock from exercise of stock options Proceeds From Stock Options Exercised Payment of employee taxes in connection with stock option exercise Payments Related To Tax Withholding For Share Based Compensation Repayments of note payable Repayments Of Notes Payable Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase (decrease) in cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash at end of period Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Non-cash financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Notes payable settled with new notes payable Notes Reduction Notes payable settled with common stock Notes Payable Settled With Common Stock Noncash Financing Activities PPP loan forgiveness P P P Loan Forgiveness Accrued deferred initial public offering costs Accrued Deferred Initial Public Offering Costs Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Business Nature Of Operations Liquidity and going concern. Disclosure of liquidity and going concern. Disclosure Of Liquidity And Going Concern [Abstract] Liquidity and Going Concern Liquidity And Going Concern [Text Block] Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies Basis Of Presentation And Significant Accounting Policies [Text Block] Supplemental Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Debt Disclosure [Abstract] Notes Payable Debt Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Deficit Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Warrants. Warrants And Rights Note Disclosure [Abstract] Warrants Warrants [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Basis of presentation and principles of consolidation. Basis of Presentation of Interim Financial Statements Basis Of Presentation And Principles Of Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Concentrations of Credit Risk Concentration Risk Credit Risk Revenue Recognition Revenue From Contract With Customer Policy [Text Block] Schedule of accrued expenses and other current liabilities. Schedule of Accrued Expenses and Other Current Liabilities Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block] Summary of Notes Payable Schedule Of Debt Table [Text Block] Summary of Future Principal Payments on Notes Payable Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block] Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Working capital. Disclosure of liquidity and going concern. Disclosure of liquidity and going concern. Disclosure Of Liquidity And Going Concern [Table] Disclosure Of Liquidity And Going Concern [Table] IPO I P O [Member] Disclosure Of Liquidity And Going Concern [Line Items] Disclosure Of Liquidity And Going Concern [Line Items] Working capital Working Capital Accounts payable and accrued expenses Accounts Payable And Accrued Liabilities Current And Noncurrent Notes payable Notes Payable Treasury share held Treasury Stock Value Summary of significant accounting policies. Schedule of summary of significant accounting policy. Schedule Of Summary Of Significant Accounting Policy [Table] Schedule Of Summary Of Significant Accounting Policy [Table] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Sales Revenue Sales Revenue Net [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Reverse stock split ratio Stockholders Equity Note Stock Split Conversion Ratio1 Concentration risk, percentage Concentration Risk Percentage1 Accrued consulting current. Accrued research and development current. Accrued interest current. Accrued consulting Accrued Consulting Current Accrued legal and professional fees Accrued Professional Fees Current Accrued research and development Accrued Research And Development Current Accrued interest Accrued Interest Current Accrued bonuses Accrued Bonuses Current Accrued other Other Accrued Liabilities Current Total accrued expenses and other current liabilities Notes Payable [Abstract] Debt Instrument [Table] Debt Instrument [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Insurance premium financing and security agreement. Insurance Premium Financing and Security Agreement Insurance Premium Financing And Security Agreement [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Notes payable aon. Notes Payable A O N Notes Payable A O N [Member] Two thousand and twenty note. EX-101.PRE 10 ikt-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 ikt-10q_20210630_htm.xml IDEA: XBRL DOCUMENT 0001750149 2021-01-01 2021-06-30 0001750149 2021-07-31 0001750149 2021-06-30 0001750149 2020-12-31 0001750149 2021-04-01 2021-06-30 0001750149 2020-04-01 2020-06-30 0001750149 2020-01-01 2020-06-30 0001750149 us-gaap:CommonStockMember 2020-12-31 0001750149 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001750149 us-gaap:RetainedEarningsMember 2020-12-31 0001750149 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001750149 2021-01-01 2021-03-31 0001750149 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001750149 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001750149 us-gaap:CommonStockMember 2021-03-31 0001750149 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001750149 us-gaap:RetainedEarningsMember 2021-03-31 0001750149 2021-03-31 0001750149 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001750149 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2021-04-01 2021-06-30 0001750149 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2021-04-01 2021-06-30 0001750149 us-gaap:OverAllotmentOptionMember 2021-04-01 2021-06-30 0001750149 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001750149 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001750149 us-gaap:CommonStockMember 2021-06-30 0001750149 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001750149 us-gaap:RetainedEarningsMember 2021-06-30 0001750149 us-gaap:CommonStockMember 2019-12-31 0001750149 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001750149 us-gaap:RetainedEarningsMember 2019-12-31 0001750149 2019-12-31 0001750149 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001750149 2020-01-01 2020-03-31 0001750149 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001750149 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001750149 us-gaap:CommonStockMember 2020-03-31 0001750149 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001750149 us-gaap:RetainedEarningsMember 2020-03-31 0001750149 2020-03-31 0001750149 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001750149 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001750149 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001750149 us-gaap:CommonStockMember 2020-06-30 0001750149 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001750149 us-gaap:RetainedEarningsMember 2020-06-30 0001750149 2020-06-30 0001750149 2021-04-01 2021-04-30 0001750149 2021-04-30 0001750149 us-gaap:OverAllotmentOptionMember 2021-06-30 0001750149 us-gaap:IPOMember 2020-12-31 0001750149 2020-08-24 2020-08-24 0001750149 2020-08-24 0001750149 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001750149 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0001750149 ikt:FifthRestatedNoteMember 2020-12-31 0001750149 ikt:PayrollProtectionProgramLoanNoteMember 2020-12-31 0001750149 ikt:CEORestatedNoteMember 2021-06-30 0001750149 ikt:CEORestatedNoteMember 2020-12-31 0001750149 ikt:TwoThousandAndTwentyNoteMember 2020-01-01 0001750149 ikt:TwoThousandAndNineteenNoteMember 2020-01-01 2020-01-01 0001750149 ikt:TwoThousandAndNineteenNoteMember 2020-01-01 0001750149 ikt:TwoThousandAndTwentyNoteMember 2020-01-01 2020-01-01 0001750149 ikt:TwoThousandAndTwentyNoteMember 2020-06-01 2020-06-30 0001750149 ikt:FifthRestatedNoteMember 2020-06-30 0001750149 ikt:CEONoteMember 2020-02-05 0001750149 ikt:CEONoteMember 2020-02-05 2020-02-05 0001750149 ikt:CEONoteMember 2021-01-01 2021-06-30 0001750149 ikt:CEORestatedNoteMember 2020-06-13 0001750149 2020-02-05 2020-02-05 0001750149 2020-02-05 0001750149 ikt:PrincipalBalanceMember 2021-06-30 0001750149 ikt:PrincipalBalanceMember 2020-12-31 0001750149 ikt:PaycheckProtectionProgramMember 2020-05-04 2020-05-04 0001750149 ikt:PaycheckProtectionProgramMember 2020-05-04 0001750149 srt:MinimumMember ikt:PaycheckProtectionProgramMember 2020-05-04 2020-05-04 0001750149 ikt:PaycheckProtectionProgramMember 2021-01-01 2021-06-30 0001750149 ikt:PaycheckProtectionProgramMember 2020-12-31 0001750149 2020-08-20 2020-08-20 0001750149 2020-08-20 0001750149 us-gaap:PrivatePlacementMember 2020-01-01 2020-01-31 0001750149 us-gaap:PrivatePlacementMember 2020-01-31 0001750149 ikt:ConsultingServicesMember 2021-01-01 2021-06-30 0001750149 us-gaap:SellingGeneralAndAdministrativeExpensesMember ikt:ConsultingServicesMember 2021-01-01 2021-06-30 0001750149 us-gaap:OverAllotmentOptionMember 2020-01-01 2020-06-30 0001750149 us-gaap:OverAllotmentOptionMember 2020-06-30 0001750149 2021-06-25 2021-06-25 0001750149 2021-06-25 0001750149 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001750149 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001750149 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-06-30 0001750149 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-06-30 0001750149 ikt:UnderwritersMember 2021-01-01 2021-06-30 0001750149 ikt:UnderwritersMember 2021-06-30 0001750149 ikt:OptionsToPurchaseSharesOfStockMember 2021-01-01 2021-06-30 0001750149 ikt:OptionsToPurchaseSharesOfStockMember 2020-01-01 2020-06-30 0001750149 ikt:WarrantsToPurchaseSharesOfStockMember 2021-01-01 2021-06-30 0001750149 ikt:WarrantsToPurchaseSharesOfStockMember 2020-01-01 2020-06-30 shares iso4217:USD iso4217:USD shares pure ikt:Vote false Q2 0001750149 --12-31

0.8741

P7Y

us-gaap:GrantMember

10-Q true 2021-06-30 2021 false 001-39676 INHIBIKASE THERAPEUTICS, INC. DE 26-3407249 3350 Riverwood Parkway SE Suite 1900 Atlanta GA 30339 678 392-3419 Common Stock, $0.001 par value IKT NASDAQ Yes Yes Non-accelerated Filer true true false false 25133345

46836556

13953513

586581

958779

774356

833963

54837

49215879

14782706

897226

1720680

872771

632934

142619

2325741

42534

1912616

4721889

248911

276461

2161527

4998350

0.001

10000000

0.001

100000000

30000000

25133345

10050849

25134

10051

67334089

24805929

-20304871

-15031624

47054352

9784356

49215879

14782706

1363037

219585

2770202

490372

1363037

219585

2770202

490372

2382433

263175

4814293

546289

1608972

370331

3209548

898019

3991405

633506

8023841

1444308

-2628368

-413921

-5253639

-953936

7811

7948

19608

15373

-2636179

-421869

-5273247

-969309

-0.22

-0.05

-0.47

-0.12

12241935

8181938

11153986

8181836

10050849

10051

24805929

-15031624

9784356

591124

237768

9000

60382

60391

-2637068

10059849

10060

25695203

-17668692

8036571

322483

239415

15000000

15000

41120357

41135357

73496

-43369

-43295

-2636179

25133345

25134

67334089

-20304871

47054352

8180937

8181

7685533

-12183730

-4490016

139758

190993

874

4870

4871

-547440

8181811

8182

8021154

-12731170

-4701834

139759

89515

11594

63789

63800

-421869

8193405

8193

8314217

-13153039

-4830629

-5273247

-969309

913607

279517

60391 75000 27550

477183

280509

586581

779126

5640

184423

-837705

-211076

239837

209149

-2183122

83508

-8180736

-258342

272800

41149608

4870

30000

34357

77652

42534

41063779

247670

32883043

-10672

13953513

18457

46836556

7785

19608

3132

42534

63800 27550 303417

-20304871

46836556

1769997

248911

1546730

772420

41100000 14600000

Basis of Presentation of Interim Financial Statements The accompanying unaudited condensed financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2020 balance sheet was derived from December 31, 2020 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2021. The condensed unaudited financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report filed on SEC Form 10-K. These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The condensed financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. On August 21, 2020, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-1.14396 (1:1.14396) reverse stock split of its common stock, par value $.001 per share, effective August 24, 2020. All warrant, option, share, and per share information in the Company’s financial statements gives retroactive effect to the one-for-1.14396 reverse stock split that was effected on August 24, 2020. The condensed financial statements have been prepared in conformity with US GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.

0.001

Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.

0.90

Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s condensed statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received.

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Supplemental Balance Sheet Information </td></tr></table></div> Accrued expenses and other current liabilities consist of the following: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">June 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued consulting</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,525</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,405</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal and professional fees</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383,286</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542,189</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,491</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,673</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonuses</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,907</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,497</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,079</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872,771</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">632,934</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Accrued expenses and other current liabilities consist of the following: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">June 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued consulting</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,525</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,405</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal and professional fees</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383,286</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542,189</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,491</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,673</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonuses</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,907</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,497</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,079</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872,771</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">632,934</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 222525 115405

383286

542189 83491 653 1673

101907

5497

49079

872771

632934

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Notes Payable </td></tr></table></div> Notes payable outstanding were $248,911 and $318,995 at June 30, 2021 and December 31, 2020, respectively. <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">June 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fifth Restated Note</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,534</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PPP Note</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,550</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO Restated Note</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total notes payable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318,995</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Future principal payments on the notes payable as of June 30, 2021, are as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total notes payable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Revolving Demand Promissory Note During 2019 and 2020, the Company entered into a series of promissory notes that were renegotiated and partially settled over 2019 and 2020. On January 1, 2020, the Company issued a note (the “2020 Note”) in the face amount of $103,586 bearing 5.25% APR simple interest as settlement in full on the 2019 Note principal of $98,419 plus accrued interest of $5,167 that matured on January 1, 2020. The 2020 Note was scheduled to mature on January 1, 2021. Upon occurrence of certain conditions including the sale of a division of the Company or upon the date on which the Company closes on certain financings, the due date for some or all of the unpaid principal and accrued and unpaid interest may be accelerated. The Company assessed the terms and features of the 2020 Note and determined that none of the terms and features represented embedded derivatives that require bifurcation. On June 30, 2020, the holder of the 2020 Note and the Company entered into an agreement to settle the 2020 Note early. As full consideration and settlement of the 2020 Note’s June 30, 2020 principal balance plus accrued and unpaid interest in the amount of $106,334, the Company issued a new promissory note to the holder in the amount of $42,534 (the “Fifth Restated Note”) with substantially similar terms as the 2020 Note. In addition, the holder subscribed for the purchase of 11,594 unregistered shares of the Company’s common stock at a subscription price of $63,800, or $5.50 per share. The issuance of shares under the subscription agreement and the issuance of the Fifth Restated Note satisfied the payoff of the 2020 Note without premium or discount. The balance of the Fifth Restated Note was $42,534 on December 31, 2020 and is included in Notes payable. The Fifth Restated Note was scheduled to mature on the earlier of a significant transaction, including an initial public offering, sale of substantially all assets or change of control, or January 1, 2021. The Company consummated its IPO on December 28, 2020 and the principal balance of the Fifth Restated Note plus accrued and unpaid interest was settled in full in cash on January 1, 2021. Note Payable to CEO On February 5, 2020 (the “Issue Date”), the Company issued a note payable to its CEO (the “CEO Note”) in the face amount of $245,250 bearing 1.59% APR simple interest in exchange for cash. The net proceeds of $245,250 were used as working capital by the Company. The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note. If an event of default occurs and is continuing, the Company agrees to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan. The Company assessed the terms and features of the CEO Note and determined that none of the terms and features represented embedded derivatives that require bifurcation. On June 13, 2020, the holder of the CEO Note and the Company entered into a restated agreement (the “CEO Restated Note”). The CEO Restated Note in the amount of $248,911 extends the stated maturity date of the CEO Note from the earlier of the sixth month following the (original) Issue Date or the date the Company has sufficient funds to repay the note to the earlier of the 30th month following the (original) Issue Date or the date the Company has sufficient funds to repay the CEO Restated Note. The Issue Date, February 5, 2020, is unchanged. In addition, the interest rate was reduced, effective as of the Issue Date, from 1.59% APR to 0.25%. The CEO Restated Note also changed the exercise price of the warrant from $4.87 to $4.81 per share in the case of any default. The other provisions of the CEO Restated Note are the same, in all material respects, to the CEO Note. The Company and its CEO have agreed that the CEO Restated Note will not be repaid for a minimum of 12 months following the closing of its IPO. The principal balance of the CEO Note was $248,911 at June 30, 2021 and at December 31, 2020 and is included on the condensed balance sheets in Notes payable, net of current portion. The Payroll Protection Program Loan (the “PPP Loan”) On May 4, 2020 the Company received $27,550 in loan proceeds as part of the Federal CARES Act Paycheck Protection Program (the “PPP Act” or “PPP”) with a 1% annual interest rate. Some or all of this loan qualified for forgiveness if the Company expended not less than 60% of the loan proceeds on qualified payroll costs. During the six months ended June 30, 2021, it was determined by the lender and by the Small Business Administration that the Company met the contractual conditions for forgiveness of the entire PPP Loan plus accrued interest and it was forgiven. The $27,550 principal balance of the PPP Loan at December 31, 2020 is included on the condensed balance sheet in Notes payable, net of current portion.

Notes payable outstanding were $248,911 and $318,995 at June 30, 2021 and December 31, 2020, respectively. <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">June 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fifth Restated Note</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,534</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PPP Note</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,550</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO Restated Note</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total notes payable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318,995</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

248911

318995

42534

27550

248911

318995

Future principal payments on the notes payable as of June 30, 2021, are as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total notes payable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,911</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

248911

103586

0.0525

98419

5167

2020-01-01

2021-01-01

106334

42534

11594

63800

5.50

42534

245250

0.0159

245250

The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note.

If an event of default occurs and is continuing, the Company agrees to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan.

4.87

1.50

248911

2020-02-05

0.0159

0.0025

4.87

4.81

248911

27550

0.01

Some or all of this loan qualified for forgiveness if the Company expended not less than 60% of the loan proceeds on qualified payroll costs. 0.60

27550

5186570

4318357

1.14396

0.001

874

5.57

4870

9000

60391

73496

15000000

3.00

41100000

3900000

68628

6.82

259674

90708

2.92

160000

The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480,415</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,041</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433,192</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,476</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">913,607</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,517</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

480415

130041

433192

149476

913607

279517

5.67

101478

237768

750000

100

2022-06-15

3.75

0 0

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Net Loss Per Share </td></tr></table></div> The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,273,247</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(969,309</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outstanding – basic and diluted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,153,986</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,181,836</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share applicable to common <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stockholders – basic and diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.47</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.12</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase shares of stock</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,624,657</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,369,144</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase shares of stock</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,561,913</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,723</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,186,570</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,843,867</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,273,247</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(969,309</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outstanding – basic and diluted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,153,986</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,181,836</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share applicable to common <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stockholders – basic and diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.47</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.12</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>

-5273247

-969309

11153986

8181836

-0.47

-0.12

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase shares of stock</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,624,657</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,369,144</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase shares of stock</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,561,913</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,723</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,186,570</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,843,867</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

3624657

3369144

1561913

474723

5186570

3843867

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Jul. 31, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	IKT
Entity Registrant Name	INHIBIKASE THERAPEUTICS, INC.
Entity Central Index Key	0001750149
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		25,133,345
Entity File Number	001-39676
Entity Current Reporting Status	Yes
Entity Tax Identification Number	26-3407249
Entity Address, Address Line One	3350 Riverwood Parkway SE
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	678
Local Phone Number	392-3419
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 46,836,556	$ 13,953,513
Grants receivable	586,581
Prepaid research and development	958,779	774,356
Prepaid expenses and other current assets	833,963	54,837
Total assets	49,215,879	14,782,706
Current liabilities:
Accounts payable	897,226	1,720,680
Accrued expenses and other current liabilities	872,771	632,934
Deferred revenue	142,619	2,325,741
Notes payable		42,534
Total	1,912,616	4,721,889
Notes payable, net of current portion	248,911	276,461
Total liabilities	2,161,527	4,998,350
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2021, and December 31, 2020; 0 shares issued and outstanding at June 30, 2021, and December 31, 2020
Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 25,133,345 and 10,050,849 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively.	25,134	10,051
Additional paid-in capital	67,334,089	24,805,929
Accumulated deficit	(20,304,871)	(15,031,624)
Total	47,054,352	9,784,356
Total liabilities and stockholders' equity	$ 49,215,879	$ 14,782,706

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	30,000,000
Common stock, shares issued	25,133,345	10,050,849
Common stock, shares outstanding	25,133,345	10,050,849

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Condensed Statements of Operations - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Total revenue	$ 1,363,037	$ 219,585	$ 2,770,202	$ 490,372
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember
Costs and expenses:
Research and development	$ 2,382,433	$ 263,175	$ 4,814,293	$ 546,289
Selling, general and administrative	1,608,972	370,331	3,209,548	898,019
Total costs and expenses	3,991,405	633,506	8,023,841	1,444,308
Loss from operations	(2,628,368)	(413,921)	(5,253,639)	(953,936)
Interest expense	(7,811)	(7,948)	(19,608)	(15,373)
Net loss	$ (2,636,179)	$ (421,869)	$ (5,273,247)	$ (969,309)
Net loss per share – basic and diluted	$ (0.22)	$ (0.05)	$ (0.47)	$ (0.12)
Weighted-average number of common shares – basic and diluted	12,241,935	8,181,938	11,153,986	8,181,836

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Stockholders' Equity (Deficit) - USD ($)	Total	June 2021 Offering	Common Stock	Common Stock June 2021 Offering	Additional Paid-In Capital	Additional Paid-In Capital June 2021 Offering	Accumulated Deficit
Beginning balance at Dec. 31, 2019	$ (4,490,016)		$ 8,181		$ 7,685,533		$ (12,183,730)
Beginning balance, Shares at Dec. 31, 2019			8,180,937
Stock-based compensation expense	139,758				139,758
Warrant expense/ Issuance of warrants	190,993				190,993
Issuance of common stock	4,871		$ 1		4,870
Issuance of common stock, Shares			874
Net loss	(547,440)						(547,440)
Ending balance at Mar. 31, 2020	(4,701,834)		$ 8,182		8,021,154		(12,731,170)
Ending balance, Shares at Mar. 31, 2020			8,181,811
Beginning balance at Dec. 31, 2019	(4,490,016)		$ 8,181		7,685,533		(12,183,730)
Beginning balance, Shares at Dec. 31, 2019			8,180,937
Warrant expense/ Issuance of warrants	$ 280,509
Issuance of common stock, stock options exercised, Shares	73,496
Net loss	$ (969,309)
Ending balance at Jun. 30, 2020	(4,830,629)		$ 8,193		8,314,217		(13,153,039)
Ending balance, Shares at Jun. 30, 2020			8,193,405
Beginning balance at Mar. 31, 2020	(4,701,834)		$ 8,182		8,021,154		(12,731,170)
Beginning balance, Shares at Mar. 31, 2020			8,181,811
Stock-based compensation expense	139,759				139,759
Warrant expense/ Issuance of warrants	89,515				89,515
Conversion of notes	63,800		$ 11		63,789
Conversion of notes, Shares			11,594
Net loss	(421,869)						(421,869)
Ending balance at Jun. 30, 2020	(4,830,629)		$ 8,193		8,314,217		(13,153,039)
Ending balance, Shares at Jun. 30, 2020			8,193,405
Beginning balance at Dec. 31, 2020	$ 9,784,356		$ 10,051		24,805,929		(15,031,624)
Beginning balance, Shares at Dec. 31, 2020	10,050,849		10,050,849
Stock-based compensation expense	$ 591,124				591,124
Warrant expense/ Issuance of warrants	237,768				237,768
Issuance of common stock	60,391		$ 9		60,382
Issuance of common stock, Shares			9,000
Net loss	(2,637,068)						(2,637,068)
Ending balance at Mar. 31, 2021	8,036,571		$ 10,060		25,695,203		(17,668,692)
Ending balance, Shares at Mar. 31, 2021			10,059,849
Beginning balance at Dec. 31, 2020	$ 9,784,356		$ 10,051		24,805,929		(15,031,624)
Beginning balance, Shares at Dec. 31, 2020	10,050,849		10,050,849
Warrant expense/ Issuance of warrants	$ 477,183
Net loss	(5,273,247)
Ending balance at Jun. 30, 2021	$ 47,054,352		$ 25,134		67,334,089		(20,304,871)
Ending balance, Shares at Jun. 30, 2021	25,133,345		25,133,345
Beginning balance at Mar. 31, 2021	$ 8,036,571		$ 10,060		25,695,203		(17,668,692)
Beginning balance, Shares at Mar. 31, 2021			10,059,849
Stock-based compensation expense	322,483				322,483
Warrant expense/ Issuance of warrants	239,415				239,415
Issuance of common stock		$ 41,135,357		$ 15,000		$ 41,120,357
Issuance of common stock, Shares				15,000,000
Issuance of common stock, stock options exercised	(43,295)		$ 74		(43,369)
Issuance of common stock, stock options exercised, Shares			73,496
Net loss	(2,636,179)						(2,636,179)
Ending balance at Jun. 30, 2021	$ 47,054,352		$ 25,134		$ 67,334,089		$ (20,304,871)
Ending balance, Shares at Jun. 30, 2021	25,133,345		25,133,345

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows - USD ($)	6 Months Ended
Condensed Statements of Cash Flows - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net loss	$ (5,273,247)	$ (969,309)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	913,607	279,517
Non-cash consulting fees	60,391	75,000
Non-cash PPP loan forgiveness	(27,550)
Warrant expense	477,183	280,509
Changes in operating assets and liabilities:
Grants receivable	(586,581)
Prepaid expenses and other assets	(779,126)	(5,640)
Prepaid research and development	(184,423)
Accounts payable	(837,705)	(211,076)
Accrued expenses and other current liabilities	239,837	209,149
Deferred revenue	(2,183,122)	83,508
Net cash used in operating activities	(8,180,736)	(258,342)
Financing activities
Proceeds from notes payable		272,800
Proceeds from issuance of common stock	41,149,608	4,870
Deferred initial public offering costs		(30,000)
Issuance of common stock from exercise of stock options	34,357
Payment of employee taxes in connection with stock option exercise	(77,652)
Repayments of note payable	(42,534)
Net cash provided by financing activities	41,063,779	247,670
Net increase (decrease) in cash	32,883,043	(10,672)
Cash at beginning of period	13,953,513	18,457
Cash at end of period	46,836,556	7,785
Supplemental disclosures of cash flow information
Cash paid for interest	19,608	3,132
Non-cash financing activities
Notes payable settled with new notes payable		42,534
Notes payable settled with common stock		63,800
PPP loan forgiveness	$ 27,550
Accrued deferred initial public offering costs		$ 303,417

XML 18 R7.htm IDEA: XBRL DOCUMENT

Nature of Business

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of Business

1.	Nature of Business

XML 19 R8.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern

6 Months Ended

Jun. 30, 2021

Disclosure Of Liquidity And Going Concern [Abstract]

Liquidity and Going Concern

2.	Liquidity and Going Concern

The Company estimates that its working capital at June 30, 2021 is sufficient to fund its normal operations into the first half of fiscal 2023.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

3.	Basis of Presentation and Significant Accounting Policies

Basis of Presentation of Interim Financial Statements

Use of Estimates

Concentrations of Credit Risk

For the three months ended June 30, 2021 and 2020, the Company derived more than 90% of its total revenue from a single source, the United States Government, in the form of federal research grants.

Revenue Recognition

XML 21 R10.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Supplemental Balance Sheet Information

4.	Supplemental Balance Sheet Information

Accrued expenses and other current liabilities consist of the following:

	June 30, 2021		December 31, 2020
Accrued consulting	$	222,525	$	115,405
Accrued legal and professional fees		—		383,286
Accrued research and development		542,189		83,491
Accrued interest		653		1,673
Accrued bonuses		101,907		—
Accrued other		5,497		49,079
Total accrued expenses and other current liabilities	$	872,771	$	632,934

XML 22 R11.htm IDEA: XBRL DOCUMENT

Notes Payable

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Notes Payable

5.	Notes Payable

Notes payable outstanding were $248,911 and $318,995 at June 30, 2021 and December 31, 2020, respectively.

	June 30, 2021		December 31, 2020
Fifth Restated Note	$	—	$	42,534
PPP Note		—		27,550
CEO Restated Note		248,911		248,911
Total notes payable	$	248,911	$	318,995

Future principal payments on the notes payable as of June 30, 2021, are as follows:

Year ending December 31,
2021	$	—
2022		248,911
2023		—
2024		—
2025		—
Total notes payable	$	248,911

Revolving Demand Promissory Note

During 2019 and 2020, the Company entered into a series of promissory notes that were renegotiated and partially settled over 2019 and 2020.

Note Payable to CEO

The Payroll Protection Program Loan (the “PPP Loan”)

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

6 Months Ended

Jun. 30, 2021

Stockholders Equity Note [Abstract]

Stockholders' Deficit

6.	Stockholders’ Deficit

Reverse Stock Split

Share Issuances

During the six months ended June 30, 2020 the Company issued 73,496 shares of its stock in connection with the exercise of non-qualified stock options.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

7.	Stock-Based Compensation

2020 Equity Incentive Plan

The Company’s 2020 Equity Incentive Plan (the “2020 Plan”) was established for granting stock incentive awards to directors, officers, employees and consultants to the Company.

Stock Options

Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees:

	Six Months Ended June 30,
	2021		2020
Research and development	$	480,415	$	130,041
Selling, general and administrative		433,192		149,476
Total stock-based compensation expense	$	913,607	$	279,517

XML 25 R14.htm IDEA: XBRL DOCUMENT

Warrants

6 Months Ended

Jun. 30, 2021

Warrants And Rights Note Disclosure [Abstract]

Warrants

Warrants Issued

Warrants Exercised

No warrants were exercised for the three months ended June 30, 2021 and 2020.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Net Loss Per Share

9.	Net Loss Per Share

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:

	Six Months Ended June 30,
	2021			2020
Numerator:
Net loss	$	(5,273,247	)	$	(969,309	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		11,153,986			8,181,836
Net loss per share applicable to common stockholders – basic and diluted	$	(0.47	)	$	(0.12	)

	Six Months Ended June 30,
	2021		2020
Options to purchase shares of stock		3,624,657		3,369,144
Warrants to purchase shares of stock		1,561,913		474,723
Total		5,186,570		3,843,867

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

10.	Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

11.	Commitments and Contingencies

Impact of the COVID-19 Pandemic on Our Operations

Litigation

XML 29 R18.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation of Interim Financial Statements	Basis of Presentation of Interim Financial Statements The accompanying unaudited condensed financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2020 balance sheet was derived from December 31, 2020 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2021. The condensed unaudited financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report filed on SEC Form 10-K. These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The condensed financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. On August 21, 2020, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-1.14396 (1:1.14396) reverse stock split of its common stock, par value $.001 per share, effective August 24, 2020. All warrant, option, share, and per share information in the Company’s financial statements gives retroactive effect to the one-for-1.14396 reverse stock split that was effected on August 24, 2020. The condensed financial statements have been prepared in conformity with US GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk For the three months ended June 30, 2021 and 2020, the Company derived more than 90% of its total revenue from a single source, the United States Government, in the form of federal research grants.
Revenue Recognition	Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s condensed statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received.

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

+ Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information (Tables)

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

	June 30, 2021		December 31, 2020
Accrued consulting	$	222,525	$	115,405
Accrued legal and professional fees		—		383,286
Accrued research and development		542,189		83,491
Accrued interest		653		1,673
Accrued bonuses		101,907		—
Accrued other		5,497		49,079
Total accrued expenses and other current liabilities	$	872,771	$	632,934

XML 31 R20.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Summary of Notes Payable

Notes payable outstanding were $248,911 and $318,995 at June 30, 2021 and December 31, 2020, respectively.

	June 30, 2021		December 31, 2020
Fifth Restated Note	$	—	$	42,534
PPP Note		—		27,550
CEO Restated Note		248,911		248,911
Total notes payable	$	248,911	$	318,995

Summary of Future Principal Payments on Notes Payable

Future principal payments on the notes payable as of June 30, 2021, are as follows:

Year ending December 31,
2021	$	—
2022		248,911
2023		—
2024		—
2025		—
Total notes payable	$	248,911

XML 32 R21.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees

The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees:

	Six Months Ended June 30,
	2021		2020
Research and development	$	480,415	$	130,041
Selling, general and administrative		433,192		149,476
Total stock-based compensation expense	$	913,607	$	279,517

XML 33 R22.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:

	Six Months Ended June 30,
	2021			2020
Numerator:
Net loss	$	(5,273,247	)	$	(969,309	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		11,153,986			8,181,836
Net loss per share applicable to common stockholders – basic and diluted	$	(0.47	)	$	(0.12	)

Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders

	Six Months Ended June 30,
	2021		2020
Options to purchase shares of stock		3,624,657		3,369,144
Warrants to purchase shares of stock		1,561,913		474,723
Total		5,186,570		3,843,867

XML 34 R23.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital		$ 47,303,263
Accumulated deficit		(20,304,871)			$ (15,031,624)
Cash		46,836,556			13,953,513
Accounts payable and accrued expenses		1,769,997
Notes payable		248,911			318,995
Issuance of common stock	$ 1,546,730		$ 60,391	$ 4,871
Treasury share held	$ 772,420
June 2021 Offering
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital		41,100,000
Issuance of common stock		$ 41,135,357
IPO
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital					$ 14,600,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)			3 Months Ended
	Aug. 24, 2020 $ / shares	Aug. 20, 2020 $ / shares	Jun. 30, 2021 $ / shares	Jun. 30, 2020 $ / shares	Dec. 31, 2020 $ / shares
Summary Of Significant Accounting Policies [Line Items]
Reverse stock split ratio	0.8741	1.14396
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 5.50	$ 0.001
Customer Concentration Risk \| Sales Revenue
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage			90.00%	90.00%

XML 36 R25.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accrued consulting	$ 222,525	$ 115,405
Accrued legal and professional fees		383,286
Accrued research and development	542,189	83,491
Accrued interest	653	1,673
Accrued bonuses	101,907
Accrued other	5,497	49,079
Total accrued expenses and other current liabilities	$ 872,771	$ 632,934

XML 37 R26.htm IDEA: XBRL DOCUMENT

Notes Payable - Additional Information (Details) - USD ($)				1 Months Ended	6 Months Ended
	May 04, 2020	Feb. 05, 2020	Jan. 01, 2020	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Aug. 24, 2020	Aug. 20, 2020	Jun. 13, 2020	Mar. 31, 2020
Debt Instrument [Line Items]
Notes payable outstanding					$ 248,911	$ 318,995
Annual interest rate		1.59%
Shares subscribed for purchase				11,594
Share subscription price				$ 63,800
Common stock, par value				$ 5.50	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Notes payable outstanding balance						$ 42,534
Strike price		$ 4.87			$ 3.75					$ 5.67
Issue date		Feb. 05, 2020
Notes payable, net of current portion					$ 248,911	276,461
Principal Balance
Debt Instrument [Line Items]
Notes payable, net of current portion					$ 248,911	248,911
2020 Note
Debt Instrument [Line Items]
Annual interest rate			5.25%
Debt instrument face amount			$ 103,586
Maturity date			Jan. 01, 2021
Settlement of notes including principal balance plus accrued and unpaid interest				$ 106,334
2019 Note
Debt Instrument [Line Items]
Settlement of principal amount			$ 98,419
Accrued interest			$ 5,167
Maturity date			Jan. 01, 2020
Fifth Restated Note
Debt Instrument [Line Items]
Notes payable outstanding						42,534
Debt instrument face amount				$ 42,534
Notes payable outstanding balance						42,534
CEO Note
Debt Instrument [Line Items]
Annual interest rate		1.59%
Debt instrument face amount		$ 245,250
Net proceeds		$ 245,250
Maturity description					The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note.
Strike price		$ 4.87
Percentage of number of shares to value of loan		150.00%
On event of default					If an event of default occurs and is continuing, the Company agrees to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan.
C E O Restated Note
Debt Instrument [Line Items]
Notes payable outstanding					$ 248,911	248,911
Annual interest rate									0.25%
Debt instrument face amount									$ 248,911
Strike price									$ 4.81
Paycheck Protection Program
Debt Instrument [Line Items]
Annual interest rate	1.00%
Debt instrument face amount						$ 27,550
Net proceeds	$ 27,550
Loan forgiveness terms					Some or all of this loan qualified for forgiveness if the Company expended not less than 60% of the loan proceeds on qualified payroll costs.
Paycheck Protection Program \| Minimum
Debt Instrument [Line Items]
Percentage of loan proceeds expended on qualified payroll costs	60.00%

XML 38 R27.htm IDEA: XBRL DOCUMENT

Notes Payable - Summary of Notes Payable Outstanding (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Notes payable outstanding	$ 248,911	$ 318,995
Fifth Restated Note
Debt Instrument [Line Items]
Notes payable outstanding		42,534
PPP Note
Debt Instrument [Line Items]
Notes payable outstanding		27,550
CEO Restated Note
Debt Instrument [Line Items]
Notes payable outstanding	$ 248,911	$ 248,911

XML 39 R28.htm IDEA: XBRL DOCUMENT

Notes Payable - Summary of Future Principal Payments on Notes Payable (Details)	Jun. 30, 2021 USD ($)
Notes Payable [Abstract]
2022	$ 248,911
Total notes payable	$ 248,911

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Additional Information (Details)			1 Months Ended	6 Months Ended
	Aug. 24, 2020 $ / shares	Aug. 20, 2020 $ / shares	Jan. 31, 2020 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) Vote $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2020 $ / shares shares
Class Of Stock [Line Items]
Votes per each common stock share \| Vote				1
Common stock shares reserved for issuance				5,186,570		4,318,357
Reverse stock split ratio	0.8741	1.14396
Common stock, par value \| $ / shares	$ 0.001	$ 0.001		$ 0.001	$ 5.50	$ 0.001
Reverse stock split description				On August 20, 2020, the board of directors adopted resolutions proposing that each 1.14396 shares of the Company’s issued and outstanding common stock, par value $0.001 per share, be automatically converted into one fully paid and non-assessable share of common stock, par value $0.001 (the “Reverse Stock Split”) with cash in lieu of fractional shares.
Proceeds from issuance of common stock \| $				$ 41,149,608	$ 4,870
Issuance of common stock, stock options exercised, Shares					73,496
Consulting Services
Class Of Stock [Line Items]
Additional rights or options granted				0
Shares issued in exchange for consulting services				9,000
Fair value of stock issued in exchange for consulting services \| $				$ 60,391
Consulting Services \| Selling, General and Administrative
Class Of Stock [Line Items]
Fair value of stock issued in exchange for consulting services \| $				$ 60,391
Private Placement
Class Of Stock [Line Items]
Issuance of common stock, Shares			874
Shares issued price per share \| $ / shares			$ 5.57
Proceeds from issuance of common stock \| $			$ 4,870
Additional rights or options granted			0
June 2021 Offering
Class Of Stock [Line Items]
Shares issued price per share \| $ / shares					$ 3.00
Proceeds from issuance of common stock \| $					$ 41,100,000
Issued and sold fully paid non-assessable shares of common stock					15,000,000
Offering costs, underwriting discounts and commissions \| $					$ 3,900,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Additional Information (Details) - USD ($)		3 Months Ended	6 Months Ended
	Jun. 25, 2021	Mar. 31, 2020	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of stock options granted	90,708	0	68,628
Stock option, strike price	$ 2.92		$ 6.82
Stock option, aggregate grant date fair value	$ 160,000		$ 259,674

XML 42 R31.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 913,607	$ 279,517
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	480,415	130,041
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 433,192	$ 149,476

XML 43 R32.htm IDEA: XBRL DOCUMENT

Warrants - Additional Information (Details) - USD ($)	3 Months Ended				6 Months Ended
Warrants - Additional Information (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Feb. 05, 2020
Class Of Warrant Or Right [Line Items]
Class of warrant or right issued				26,225	0
Strike price	$ 3.75			$ 5.67	$ 3.75		$ 4.87
Contractual term				7 years
Fair value of warrant			$ 101,478			$ 101,478
Warrant expense	$ 239,415	$ 237,768	$ 89,515	$ 190,993	$ 477,183	$ 280,509
Class of warrant or right, date from which warrants or rights exercisable					Jun. 15, 2022
Class of warrant or right exercised in period	0		0
Underwriters
Class Of Warrant Or Right [Line Items]
Class of warrant or right issued					750,000
Fair value of warrant	$ 100				$ 100
Selling, General and Administrative
Class Of Warrant Or Right [Line Items]
Warrant expense					$ 237,768

XML 44 R33.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net loss	$ (2,636,179)	$ (2,637,068)	$ (421,869)	$ (547,440)	$ (5,273,247)	$ (969,309)
Denominator:
Weighted-average number of common shares – basic and diluted	12,241,935		8,181,938		11,153,986	8,181,836
Net loss per share – basic and diluted	$ (0.22)		$ (0.05)		$ (0.47)	$ (0.12)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 45 R34.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	5,186,570	3,843,867
Options to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	3,624,657	3,369,144
Warrants to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	1,561,913	474,723

XML 46 R35.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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³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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 97 237 1 false 23 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Balance Sheets Sheet http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Statements of Operations Sheet http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations Condensed Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Condensed Statements of Stockholders' Equity (Deficit) Sheet http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit Condensed Statements of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 100050 - Statement - Condensed Statements of Cash Flows Sheet http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Nature of Business Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNatureOfBusiness Nature of Business Notes 7 false false R8.htm 100070 - Disclosure - Liquidity and Going Concern Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcern Liquidity and Going Concern Notes 8 false false R9.htm 100080 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 10 false false R11.htm 100100 - Disclosure - Notes Payable Notes http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayable Notes Payable Notes 11 false false R12.htm 100110 - Disclosure - Stockholders' Deficit Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficit Stockholders' Deficit Notes 12 false false R13.htm 100120 - Disclosure - Stock-Based Compensation Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 100130 - Disclosure - Warrants Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrants Warrants Notes 14 false false R15.htm 100140 - Disclosure - Net Loss Per Share Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 100150 - Disclosure - Income Taxes Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 100160 - Disclosure - Commitments and Contingencies Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 100170 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies 18 false false R19.htm 100180 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformation 19 false false R20.htm 100190 - Disclosure - Notes Payable (Tables) Notes http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableTables Notes Payable (Tables) Tables http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayable 20 false false R21.htm 100200 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensation 21 false false R22.htm 100210 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShare 22 false false R23.htm 100220 - Disclosure - Liquidity and Going Concern - Additional Information (Details) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails Liquidity and Going Concern - Additional Information (Details) Details 23 false false R24.htm 100230 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Details 24 false false R25.htm 100240 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Details 25 false false R26.htm 100250 - Disclosure - Notes Payable - Additional Information (Details) Notes http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails Notes Payable - Additional Information (Details) Details 26 false false R27.htm 100260 - Disclosure - Notes Payable - Summary of Notes Payable Outstanding (Details) Notes http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails Notes Payable - Summary of Notes Payable Outstanding (Details) Details 27 false false R28.htm 100270 - Disclosure - Notes Payable - Summary of Future Principal Payments on Notes Payable (Details) Notes http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails Notes Payable - Summary of Future Principal Payments on Notes Payable (Details) Details 28 false false R29.htm 100280 - Disclosure - Stockholders' Deficit - Additional Information (Details) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails Stockholders' Deficit - Additional Information (Details) Details 29 false false R30.htm 100290 - Disclosure - Stock-based Compensation - Additional Information (Details) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-based Compensation - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail) Details 31 false false R32.htm 100310 - Disclosure - Warrants - Additional Information (Details) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails Warrants - Additional Information (Details) Details 32 false false R33.htm 100320 - Disclosure - Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareApplicableToCommonStockholdersDetails Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details) Details 33 false false R34.htm 100330 - Disclosure - Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details) Details 34 false false R35.htm 100340 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.inhibikase.com/20210630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 35 false false All Reports Book All Reports ikt-10q_20210630.htm ikt-20210630.xsd ikt-20210630_cal.xml ikt-20210630_def.xml ikt-20210630_lab.xml ikt-20210630_pre.xml ikt-ex311_6.htm ikt-ex312_7.htm ikt-ex321_9.htm ikt-ex322_8.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ikt-10q_20210630.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 97, "dts": { "calculationLink": { "local": [ "ikt-20210630_cal.xml" ] }, "definitionLink": { "local": [ "ikt-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ikt-10q_20210630.htm" ] }, "labelLink": { "local": [ "ikt-20210630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ikt-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ikt-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 277, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 13, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 17 }, "keyCustom": 24, "keyStandard": 213, "memberCustom": 12, "memberStandard": 11, "nsprefix": "ikt", "nsuri": "http://www.inhibikase.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Supplemental Balance Sheet Information", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformation", "shortName": "Supplemental Balance Sheet Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Notes Payable", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Stockholders' Deficit", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficit", "shortName": "Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Stock-Based Compensation", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ikt:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Warrants", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ikt:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Net Loss Per Share", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Income Taxes", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Commitments and Contingencies", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ikt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ikt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ikt:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Supplemental Balance Sheet Information (Tables)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables", "shortName": "Supplemental Balance Sheet Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ikt:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Balance Sheets", "role": "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "lang": null, "name": "us-gaap:GrantsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Notes Payable (Tables)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ikt:LiquidityAndGoingConcernTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "ikt:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Liquidity and Going Concern - Additional Information (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "shortName": "Liquidity and Going Concern - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ikt:LiquidityAndGoingConcernTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "ikt:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityReverseStockSplit", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20200820_20200820", "decimals": "5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskPercentage1", "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210401_20210630", "decimals": "2", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ikt:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "ikt:AccruedConsultingCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ikt:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "ikt:AccruedConsultingCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "ikt:LiquidityAndGoingConcernTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Notes Payable - Additional Information (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "shortName": "Notes Payable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20200205", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ikt:LiquidityAndGoingConcernTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Notes Payable - Summary of Notes Payable Outstanding (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails", "shortName": "Notes Payable - Summary of Notes Payable Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_us-gaapDebtInstrumentAxis_iktPayrollProtectionProgramLoanNoteMember_20201231", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Notes Payable - Summary of Future Principal Payments on Notes Payable (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails", "shortName": "Notes Payable - Summary of Future Principal Payments on Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "ikt:CommonStockPerShareEntitledToVote", "reportCount": 1, "unique": true, "unitRef": "U_iktVote", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Stockholders' Deficit - Additional Information (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "shortName": "Stockholders' Deficit - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "ikt:CommonStockPerShareEntitledToVote", "reportCount": 1, "unique": true, "unitRef": "U_iktVote", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210625_20210625", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Stock-based Compensation - Additional Information (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210625_20210625", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail", "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "ikt:WarrantsTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20200101_20200331", "decimals": "INF", "first": true, "lang": null, "name": "ikt:ClassOfWarrantOrRightIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Warrants - Additional Information (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "shortName": "Warrants - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ikt:WarrantsTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20200101_20200331", "decimals": "INF", "first": true, "lang": null, "name": "ikt:ClassOfWarrantOrRightIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210401_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareApplicableToCommonStockholdersDetails", "shortName": "Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails", "shortName": "Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210401_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Statements of Operations", "role": "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations", "shortName": "Condensed Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210401_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Statements of Stockholders' Equity (Deficit)", "role": "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit", "shortName": "Condensed Statements of Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20200101_20200331", "decimals": "0", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Statements of Cash Flows", "role": "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Nature of Business", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ikt:LiquidityAndGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Liquidity and Going Concern", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcern", "shortName": "Liquidity and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ikt:LiquidityAndGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Basis of Presentation and Significant Accounting Policies", "role": "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ikt-10q_20210630.htm", "contextRef": "C_0001750149_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 23, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ikt_AccruedConsultingCurrent": { "auth_ref": [], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued consulting current.", "label": "Accrued Consulting Current", "terseLabel": "Accrued consulting" } } }, "localname": "AccruedConsultingCurrent", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "ikt_AccruedDeferredInitialPublicOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued deferred initial public offering costs.", "label": "Accrued Deferred Initial Public Offering Costs", "terseLabel": "Accrued deferred initial public offering costs" } } }, "localname": "AccruedDeferredInitialPublicOfferingCosts", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ikt_AccruedInterestCurrent": { "auth_ref": [], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest current.", "label": "Accrued Interest Current", "terseLabel": "Accrued interest" } } }, "localname": "AccruedInterestCurrent", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "ikt_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development current.", "label": "Accrued Research And Development Current", "terseLabel": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "ikt_AdditionalRightsOrOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional rights or options granted.", "label": "Additional Rights Or Options Granted", "terseLabel": "Additional rights or options granted" } } }, "localname": "AdditionalRightsOrOptionsGranted", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ikt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of presentation and principles of consolidation.", "label": "Basis Of Presentation And Principles Of Consolidation Policy [Text Block]", "terseLabel": "Basis of Presentation of Interim Financial Statements" } } }, "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ikt_CEONoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO note.", "label": "C E O Note [Member]", "terseLabel": "CEO Note" } } }, "localname": "CEONoteMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_CEORestatedNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ceo restated note.", "label": "C E O Restated Note [Member]", "terseLabel": "C E O Restated Note", "verboseLabel": "CEO Restated Note" } } }, "localname": "CEORestatedNoteMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails" ], "xbrltype": "domainItemType" }, "ikt_ClassOfWarrantOrRightExercisedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercised in period.", "label": "Class Of Warrant Or Right Exercised In Period", "terseLabel": "Class of warrant or right exercised in period" } } }, "localname": "ClassOfWarrantOrRightExercisedInPeriod", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ikt_ClassOfWarrantOrRightIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right issued.", "label": "Class Of Warrant Or Right Issued", "terseLabel": "Class of warrant or right issued" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ikt_CommonStockPerShareEntitledToVote": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock per share entitled to vote.", "label": "Common Stock Per Share Entitled To Vote", "terseLabel": "Votes per each common stock share" } } }, "localname": "CommonStockPerShareEntitledToVote", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "ikt_ConsultingServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting services.", "label": "Consulting Services [Member]", "terseLabel": "Consulting Services" } } }, "localname": "ConsultingServicesMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_DebtInstrumentFinalPaymentDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, final payment date.", "label": "Debt Instrument Final Payment Date", "terseLabel": "Final payment due date" } } }, "localname": "DebtInstrumentFinalPaymentDate", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "ikt_DisclosureOfLiquidityAndGoingConcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of liquidity and going concern.", "label": "Disclosure Of Liquidity And Going Concern [Abstract]" } } }, "localname": "DisclosureOfLiquidityAndGoingConcernAbstract", "nsuri": "http://www.inhibikase.com/20210630", "xbrltype": "stringItemType" }, "ikt_DisclosureOfLiquidityAndGoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of liquidity and going concern.", "label": "Disclosure Of Liquidity And Going Concern [Line Items]", "terseLabel": "Disclosure Of Liquidity And Going Concern [Line Items]" } } }, "localname": "DisclosureOfLiquidityAndGoingConcernLineItems", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ikt_DisclosureOfLiquidityAndGoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of liquidity and going concern.", "label": "Disclosure Of Liquidity And Going Concern [Table]", "terseLabel": "Disclosure Of Liquidity And Going Concern [Table]" } } }, "localname": "DisclosureOfLiquidityAndGoingConcernTable", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ikt_FifthRestatedNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fifth restated note.", "label": "Fifth Restated Note [Member]", "terseLabel": "Fifth Restated Note" } } }, "localname": "FifthRestatedNoteMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails" ], "xbrltype": "domainItemType" }, "ikt_IncreaseDecreaseInPrepaidResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in prepaid research and development.", "label": "Increase Decrease In Prepaid Research And Development", "negatedLabel": "Prepaid research and development" } } }, "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopment", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ikt_InsurancePremiumFinancingAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance premium financing and security agreement.", "label": "Insurance Premium Financing And Security Agreement [Member]", "terseLabel": "Insurance Premium Financing and Security Agreement" } } }, "localname": "InsurancePremiumFinancingAndSecurityAgreementMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_IssuedAndSoldFullyPaidNonAssessableSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued and sold fully paid non-assessable shares of common stock.", "label": "Issued And Sold Fully Paid Non Assessable Shares Of Common Stock", "terseLabel": "Issued and sold fully paid non-assessable shares of common stock" } } }, "localname": "IssuedAndSoldFullyPaidNonAssessableSharesOfCommonStock", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ikt_LiquidityAndGoingConcernTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity and going concern.", "label": "Liquidity And Going Concern [Text Block]", "terseLabel": "Liquidity and Going Concern" } } }, "localname": "LiquidityAndGoingConcernTextBlock", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "ikt_LoanForgivenessTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan forgiveness terms.", "label": "Loan Forgiveness Terms", "terseLabel": "Loan forgiveness terms" } } }, "localname": "LoanForgivenessTerms", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ikt_NonCashConsultingFees": { "auth_ref": [], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash consulting fees.", "label": "Non Cash Consulting Fees", "terseLabel": "Non-cash consulting fees" } } }, "localname": "NonCashConsultingFees", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ikt_NonCashPPPLoanForgiveness": { "auth_ref": [], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-cash PPP loan forgiveness.", "label": "Non Cash P P P Loan Forgiveness", "negatedLabel": "Non-cash PPP loan forgiveness" } } }, "localname": "NonCashPPPLoanForgiveness", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ikt_NotesPayableAONMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes payable aon.", "label": "Notes Payable A O N [Member]", "terseLabel": "Notes Payable A O N" } } }, "localname": "NotesPayableAONMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_NotesPayableSettledWithCommonStockNoncashFinancingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Notes payable settled with common stock in non-cash financing activities.", "label": "Notes Payable Settled With Common Stock Noncash Financing Activities", "terseLabel": "Notes payable settled with common stock" } } }, "localname": "NotesPayableSettledWithCommonStockNoncashFinancingActivities", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ikt_OfferingCostsUnderwritingDiscountsAndCommissions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs, underwriting discounts and commissions.", "label": "Offering Costs Underwriting Discounts And Commissions", "terseLabel": "Offering costs, underwriting discounts and commissions" } } }, "localname": "OfferingCostsUnderwritingDiscountsAndCommissions", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ikt_OptionsToPurchaseSharesOfStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options to purchase shares of stock.", "label": "Options To Purchase Shares Of Stock [Member]", "terseLabel": "Options to Purchase Shares of Stock" } } }, "localname": "OptionsToPurchaseSharesOfStockMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "ikt_PPPLoanForgiveness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "PPP loan forgiveness.", "label": "P P P Loan Forgiveness", "terseLabel": "PPP loan forgiveness" } } }, "localname": "PPPLoanForgiveness", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ikt_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck protection program.", "label": "Paycheck Protection Program [Member]", "terseLabel": "Paycheck Protection Program" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_PayrollProtectionProgramLoanNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payroll protection program loan note.", "label": "Payroll Protection Program Loan Note [Member]", "terseLabel": "PPP Note" } } }, "localname": "PayrollProtectionProgramLoanNoteMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails" ], "xbrltype": "domainItemType" }, "ikt_PercentageOfLoanProceedsExpendedOnQualifiedPayrollCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of loan proceeds expended on qualified payroll costs.", "label": "Percentage Of Loan Proceeds Expended On Qualified Payroll Costs", "terseLabel": "Percentage of loan proceeds expended on qualified payroll costs" } } }, "localname": "PercentageOfLoanProceedsExpendedOnQualifiedPayrollCosts", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ikt_PercentageOfNumberOfSharesToValueOfDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of number of shares to value of debt.", "label": "Percentage Of Number Of Shares To Value Of Debt", "terseLabel": "Percentage of number of shares to value of loan" } } }, "localname": "PercentageOfNumberOfSharesToValueOfDebt", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ikt_PrincipalBalanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal balance member.", "label": "Principal Balance [Member]", "terseLabel": "Principal Balance" } } }, "localname": "PrincipalBalanceMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of accrued expenses and other current liabilities.", "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "ikt_ScheduleOfSummaryOfSignificantAccountingPolicyTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of summary of significant accounting policy.", "label": "Schedule Of Summary Of Significant Accounting Policy [Table]", "terseLabel": "Schedule Of Summary Of Significant Accounting Policy [Table]" } } }, "localname": "ScheduleOfSummaryOfSignificantAccountingPolicyTable", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ikt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options grants in period grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value", "terseLabel": "Stock option, aggregate grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ikt_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ikt_TwoThousandAndNineteenNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and nineteen note.", "label": "Two Thousand And Nineteen Note [Member]", "terseLabel": "2019 Note" } } }, "localname": "TwoThousandAndNineteenNoteMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_TwoThousandAndTwentyNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty note.", "label": "Two Thousand And Twenty Note [Member]", "terseLabel": "2020 Note" } } }, "localname": "TwoThousandAndTwentyNoteMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_UnderwritersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters.", "label": "Underwriters [Member]", "terseLabel": "Underwriters" } } }, "localname": "UnderwritersMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ikt_WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants.", "label": "Warrants [Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsTextBlock", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrants" ], "xbrltype": "textBlockItemType" }, "ikt_WarrantsToPurchaseSharesOfStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase shares of stock.", "label": "Warrants To Purchase Shares Of Stock [Member]", "terseLabel": "Warrants to Purchase Shares of Stock" } } }, "localname": "WarrantsToPurchaseSharesOfStockMember", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "ikt_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "Working Capital", "terseLabel": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://www.inhibikase.com/20210630", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block]", "terseLabel": "Summary of Future Principal Payments on Notes Payable" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "srt_MaximumMember": { "auth_ref": [ "r171", "r172", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r171", "r172", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r169", "r171", "r172", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r169", "r171", "r172", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r122", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r252", "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable And Accrued Liabilities Current And Noncurrent", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r4", "r5", "r24" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10050.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses Current", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r4", "r5", "r24" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Accrued legal and professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r12" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r69", "r70", "r71", "r181", "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r173", "r175", "r186", "r187" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r175", "r179", "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r63", "r108", "r111", "r117", "r124", "r204", "r206", "r211", "r248", "r260" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r19", "r277", "r278" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r48", "r54", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r48", "r212" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Date the warrants or rights are exercisable, in CCYY-MM-DD format.", "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable", "terseLabel": "Class of warrant or right, date from which warrants or rights exercisable" } } }, "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Strike price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Warrant Or Right [Line Items]", "terseLabel": "Class Of Warrant Or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r152", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class Of Warrant Or Right [Table]", "terseLabel": "Class Of Warrant Or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r130", "r254", "r264" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (see Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock shares reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock Shares Subscribed But Unissued", "terseLabel": "Shares subscribed for purchase" } } }, "localname": "CommonStockSharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscriptions": { "auth_ref": [ "r11", "r138" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock Shares Subscriptions", "terseLabel": "Share subscription price" } } }, "localname": "CommonStockSharesSubscriptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r11" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 25,133,345 and 10,050,849 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r98", "r99", "r121", "r209", "r210" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r98", "r99", "r121", "r209", "r210", "r276" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r98", "r99", "r121", "r209", "r210", "r276" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r94", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r98", "r99", "r121", "r209", "r210" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r98", "r99", "r121", "r209", "r210" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r154", "r155", "r166" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r41" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations": { "order": 10040.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs And Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r97", "r121" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDefaultShorttermDebtDescriptionOfViolationOrEventOfDefault": { "auth_ref": [ "r65", "r132" ], "lang": { "en-us": { "role": { "documentation": "Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a short-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver.", "label": "Debt Default Shortterm Debt Description Of Violation Or Event Of Default", "terseLabel": "On event of default" } } }, "localname": "DebtDefaultShorttermDebtDescriptionOfViolationOrEventOfDefault", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r7", "r8", "r9", "r249", "r250", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r9", "r133", "r250", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "terseLabel": "Debt instrument, carrying amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r221", "r223" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Debt instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Annual interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentIssuanceDate1": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Date the debt instrument was issued, in CCYY-MM-DD format.", "label": "Debt Instrument Issuance Date1", "terseLabel": "Issue date" } } }, "localname": "DebtInstrumentIssuanceDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r27", "r208" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument Maturity Date Description", "terseLabel": "Maturity description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r29", "r66", "r141", "r144", "r145", "r146", "r220", "r221", "r223", "r257" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation Of Revenue [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share \u2013 basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareApplicableToCommonStockholdersDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic And Diluted [Abstract]" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r84", "r85", "r86", "r87" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r69", "r70", "r71", "r73", "r78", "r80", "r88", "r125", "r140", "r147", "r181", "r182", "r183", "r194", "r195", "r213", "r214", "r215", "r216", "r217", "r218", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment Of Debt Amount", "terseLabel": "Settlement of notes including principal balance plus accrued and unpaid interest" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r52", "r136" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment Of Warrants", "terseLabel": "Warrant expense", "verboseLabel": "Warrant expense/ Issuance of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantsReceivableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Grants Receivable Current", "terseLabel": "Grants receivable" } } }, "localname": "GrantsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r191", "r192", "r193", "r196", "r198", "r200", "r201", "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r64", "r79", "r80", "r107", "r190", "r197", "r199", "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r51" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r51" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Grants receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r51" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r51" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase Decrease In Other Accounts Payable And Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r51" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r39", "r106", "r219", "r222", "r256" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r47", "r49", "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r253", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable Current And Noncurrent", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance Of Stock And Warrants For Services Or Claims", "terseLabel": "Fair value of stock issued in exchange for consulting services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r63", "r112", "r124", "r205", "r206", "r207", "r211" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r16", "r63", "r124", "r211", "r251", "r263" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r63", "r124", "r205", "r206", "r207", "r211" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r9", "r134", "r250", "r261" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt", "totalLabel": "Total notes payable" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r67", "r131" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails": { "order": 10020.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r67", "r131" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails": { "order": 10050.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal In Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r67", "r131" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails": { "order": 10040.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal In Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r67", "r131" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails": { "order": 10030.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal In Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r67" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails": { "order": 10010.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsOnNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r29" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Long Term Notes Payable", "terseLabel": "Notes payable, net of current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r91", "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature Of Operations", "terseLabel": "Nature of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r48" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r48", "r50", "r53" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r37", "r38", "r40", "r53", "r63", "r72", "r74", "r75", "r76", "r77", "r79", "r80", "r81", "r108", "r110", "r113", "r116", "r118", "r124", "r211", "r255", "r267" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareApplicableToCommonStockholdersDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r9", "r250", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "positiveLabel": "Notes payable outstanding", "terseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable [Abstract]" } } }, "localname": "NotesPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable Current", "terseLabel": "Notes payable", "verboseLabel": "Notes payable outstanding balance" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReduction": { "auth_ref": [ "r56", "r57", "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.", "label": "Notes Reduction", "terseLabel": "Notes payable settled with new notes payable" } } }, "localname": "NotesReduction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs And Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r108", "r110", "r113", "r116", "r118" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r4", "r5", "r6", "r24" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10060.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "June 2021 Offering" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "auth_ref": [ "r45" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.", "label": "Payments For Repurchase Of Initial Public Offering", "negatedLabel": "Deferred initial public offering costs" } } }, "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r45" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Payment of employee taxes in connection with stock option exercise" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r10" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2021, and December 31, 2020; 0 shares issued and outstanding at June 30, 2021, and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r2", "r17", "r18" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r1", "r3", "r126", "r127" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid research and development" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r43" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds From Issuance Of Debt", "terseLabel": "Net proceeds" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r44" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds From Notes Payable", "terseLabel": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r43", "r180" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Issuance of common stock from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r170", "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r170", "r224", "r227", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments Of Debt", "terseLabel": "Settlement of principal amount" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r46" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments Of Notes Payable", "negatedLabel": "Repayments of note payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r189", "r279" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations": { "order": 10050.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r13", "r147", "r184", "r262", "r274", "r275" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r69", "r70", "r71", "r73", "r78", "r80", "r125", "r181", "r182", "r183", "r194", "r195", "r271", "r273" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r104", "r105", "r109", "r114", "r115", "r119", "r120", "r121", "r164", "r165", "r235" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations": { "order": 10030.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r60", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue From Contract With Customer Product And Service Extensible List", "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "extensibleListItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r98", "r121" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Sales Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfSharesExcludedFromCalculationOfDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule Of Debt Table [Text Block]", "terseLabel": "Summary of Notes Payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r175", "r178", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r175", "r178", "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r31", "r61", "r89", "r90", "r137", "r138", "r139", "r141", "r142", "r143", "r144", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations": { "order": 10060.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r51" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1", "terseLabel": "Stock option, strike price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type [Axis]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short Term Debt Type [Domain]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r34", "r69", "r70", "r71", "r73", "r78", "r80", "r88", "r125", "r140", "r147", "r181", "r182", "r183", "r194", "r195", "r213", "r214", "r215", "r216", "r217", "r218", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r69", "r70", "r71", "r88", "r235" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r10", "r11", "r140", "r141", "r147" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period Shares Conversion Of Units", "terseLabel": "Conversion of notes, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period Shares Issued For Services", "terseLabel": "Shares issued in exchange for consulting services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r10", "r11", "r140", "r147" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r10", "r11", "r140", "r147", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "terseLabel": "Issuance of common stock, stock options exercised, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r34", "r140", "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period Value Conversion Of Units", "terseLabel": "Conversion of notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period Value Issued For Services", "terseLabel": "Fair value of stock issued in exchange for consulting services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r10", "r11", "r140", "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r34", "r140", "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock, stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r11", "r14", "r15", "r63", "r123", "r124", "r211" ], "calculation": { "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r62", "r147", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders Equity Note Stock Split Conversion Ratio1", "terseLabel": "Reverse stock split ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Reverse stock split description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureSupplementalBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r33", "r150", "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock Value", "terseLabel": "Treasury share held" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r92", "r93", "r95", "r96", "r100", "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants And Rights Note Disclosure [Abstract]" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants And Rights Outstanding", "terseLabel": "Fair value of warrant" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding Term", "terseLabel": "Contractual term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average number of common shares \u2013 basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareApplicableToCommonStockholdersDetails", "http://www.inhibikase.com/20210630/taxonomy/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.inhibikase.com/20210630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r281": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r282": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r283": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r284": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r285": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r286": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r287": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" } }, "version": "2.1" } ZIP 54 0001564590-21-044637-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-044637-xbrl.zip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

BIK2P7\EP27>J]44N M%Z7LLWYV%2T,:DBC4M1HK>JF'Z6$2BK]-W;QZJUH/;=)X=X,C.'Z &5!XY;% M1#'K@.&XK-BJD'=H%06]JP8%$0_E4#ZD_7VJNF!@;T7?K45+MWG-)D@()-EG M>-I;C(Q^-!ULQ7N?AD0%3>W;\_OPS(-[U_4C:J]("*[T9E2;RXW0_JNV 7.! MWZJ@;TJKY>YR2RV7]A9Z* =T#AAZV #QJFYN@TX5'+-N;GFMGH0+LI.=95H6 M!H6Z[A^58C3'"$[4)-&K45IF>OWJEV&O4Z%Y0>*X%-+"=DUPKQU;D3CJ(P%% MFM40;?%> H=^3+K3B00L4BE(@^38TZ[QGU$O+Q82A%$M[Y^Y13PF:P"1\9"M MH"G0'G0JVIE+8)=LT$*W%RKCP+PV'M@:;]W]I%#NVNZ^8[?[ZCNF6G6YGXI5 M@F_=DM7R ?VT.)6D#MK]] QITA/?D.#^%?W"!]C/Z'+/NC@%Y6U>>DS\,B"-&A)%=FZF/_$HY_\=G<]1?8 M@TO8GQ2HHAK Y-2\-(IV.FFB9N3D%?H* MC>KFH"C8LZ%AF\:=4,,-4$63[L MD<2@U<,=HU+#E,PLRTO/>\RR/%'D]]=%R7*[1\[(Q_S#=YZ(N/T6^.&&+O#U MDUG7M\9U_[:B[;8D#UE_%%)_(:Q 8J;][-!4!U$@.2,/*CQ,3[Q1*7M%[C:.H'0%TV^9.Y&"4*K+#0D83.A\IO4(E)R/]%Q,CM>W 5S?0"<VO[::$),;2++.;,9MASQK0X(26],_!?P)A/ MA+L,6U>4Q!]&[)>344T6^T6P@]CO=^ZV$_M8+(X=[[*(=KX$@4A411W4" M-DH1]!5Z2X,M5YF%65GN? +O0.V5C?$.JGQ_67H@8@"KPIC7I1K/SW)"R8?) M&^G!LA8JC>K&LHYO(-.)$%12' M858\=B5JH:P\/KG$)\UH+!R^RY7C%!URS&FFW_Q\0C:3\::ZD6BQK)\IR+8I M*GVS55!Z7(K@O:7_>RW??H7Q2H)!\@65>?W<[=R,QF;A0%*K-L6NJC,]OCP_Y,5U;$4'XQ0EI.Y]&*86&Q9X.#OY> MY[I_:NB?_LA-)29@*1@FQISH\;"2?/5K!E29#NIV-K!)%N3>*E_: K1]!E?O MO7#UWI1#8"=FK*KF[7]\/9M]^W# =A( M&N![AW]CPI+8HKJU5.8O$U[#A;=<8]LK3N)I'V\>%-6 MOM>E,[[-4[ZKCZ%N*(8:=(WNL&J26]-H^^*5[R7G_AJ#EL^;>\\T*8Y^N8@Z M;4YC&RMJ793[PD5=,U!5M*9V0IM-!LE-%&M>87!>(JS-..JU#WD7:9.>;F-H+ M*K6]5K#72JU*=K;7=HB)W/4&QG6W/#?HQ$I@>PUP48+DM$I!*^CFX$(K:*V@ MM8(^C((N]:K;AX*N&_CHW]P9HYY6T*K$)@@JH:=UI'>,N$>AP>YRW_=U?>#K MM1^J;F*^JM=/-C(!6T)GNZC:VMXW1N-KLSA8' U M-&^[5^/>]>V5V3=O)^;0-/EPU/X.YJL1FZ=-W<'\P%NZW5,'\SVBL_T=S!-) M4Z<;>0["99B3IA!LJ1O"I8&71NO?4:UK'M@\?>T]'(0>78^&3X%GL1 M4,<>;/,8K@?CD<5S_*C>I?2ZT.SWP37#\,-$HO5#0):;P.V^.M66C-%KH]\O M'PRJ'. &.\2NF.F@K*P%_/(PU72"*L,V> G < >FXX5[;TIZ7>KU6@G)0N_0 M],=0_AINZ"9:"=I?1IWKLB6?FU..M:M (;#E@DC%AL%7SK>KJ6,#*_PLMW'S MZI>0/W/O"AN/2I%*:\('QZ;+0"O,BC!U !&X5S$Q#_N1.G)XV114$@]".46 M<3$_P(P(>;G>I#3W"%88!=R,Q-@CQ ]\;;J(;D 86'Z8+A9O+@_!3=:"3[$Y MKM'Q1(_"<9UY7]>WR]A,,'7OV7($:QS1"D$[;D*:6DZZVS.&-Q6-=^/(<9W_ M.+)3\Z\NZ-2KSQ: F(=7[WD0P;Y$B\8K)&F\;N;;W$5PT\1:D&3$-\FP6@0Z M3DCU+#>V:9;J5B,W93YORZF;W>6A5T"/U'RZAIRZVXN M[G(G#*(O3H1MCM^!QGAV;-"DR<#E/W-KW\< >GCE-B/H"T-&D5L*/<13J"F: M1P7 E7*2-95H'>B5! LHUJI1HG& ZC!*" F?%'&$1,!)X&64F:>Q)>$-:C1G M#/&L@3Q8'\".'E+QJD#9X*84&:ZBL5"T2@_\V5]3QYHN&XZYIO5JZB]/2-@R MGF2E;2[0_$.=1_S8$S,2^LLQ11I.ZX'L="('Y&4Z1GE/-O5-J0CQ #9U)7_] M L*RPB/);&K86YZ!RF,XS\D);F0\(9T;?G;@;)BBK:'Q-D<$4NPDTQPV,=FP MKM%=8_G7^UY^-UG^QG'@VTSA6>-$D&O$4\I/C-AH"MIHG1F+]M"Z"3W*=NF: MB;6MG"U\MZ?9PLIYJ&-+-86APZ/2^;TW9H"V3)@,A=]'-J_UR3@]3K@1R;@[ M/4[X^,FX/WC$?O?#D('$8"0RUJ;E5@\.*@_1S 8'+0FE7\W0L;"/BN/&$;>_ MX//W):A:.Q9H#C84ITFZ\*-ENE;L"M4&CLX8 2J:=0J0,@_0ZB):>]O3GO0^"D)*B6J62;[=2-/M$ MC9X;U'"LZ;%!#4'$]J=A+U;Q-!516@4U&35ZJ,;9XU5/%CH]&^G!0N>+.RT" MSQZO>JQ00ZUQ/57H,)$>"AJ;$2RF><=N]2B#IAY:OZ@#Z4W%DYYG<,;(N_B& M_AKQ^U,FT"&K0R/1M4:65ZMJBKH4Q+;6@4E.G:WJ#;*-.[ MZSMCT+W3JO0LJ.M'G7P^'? ?N>?/'$^GG\_/>CE6;D";+DW%4SDWH(V7LT'> MQ><&FH$&K6*TBM%XTBJFC!6CT\\-0,M?]"AN7YG//#"?./-B[':8[T1' MG;"4NRR<$0P*7?;\K'R5:N=>:)T_2.E\F%"GI5SWWJ6F2X<9*]KK&;W1P+B[;?[$=IV3 M.+T T7JW.;C0>K<%J-)Z]U!Z][8TMN,0>K?NM-!;HW?;,VX'6NV>!_TUY3"Z MCN!4'B#8T#7S8@(XRR/"L@A.N>6HGD[?'/0U,4*_,;6BC__GJ(]_:P.]9=N9X^'-BYE''T#*DVU,M;*6"MCK8RU,CZ0,BY- MOMA)&:\. 165<:^OE?%94%?5L8_B3)4U,[LV J*P[_HSIU:.=2E-",W&NMQ[ MD4/.O_/,/W,K#IS(X>&;;V)>+P["Q)FP<41C2LI38+[PPTQ\V0Y6C9[X(N? MREESI$UJS*NGS#0?:WK*3$,0H:?,G"VBM,)I#B+T M0(6SQZN>*7-Z-M(S9]4R9AMK>NJW/8:(X'^88K PQ@#F/ VMJ MACR)GOH3$;-L7N).MV)H0-I;3P)H*I[T)(##G& HI?)V3.#=SX >HC79._F> M'5_SZZ+Z ???G/"?SM=(JH O_D>I .BN\,/D,TK_]QR/9:RO0: (JFIK 42_,U"TD MFHK++9-QNH_$ 2R]TBSN0UMZ.T5<1D;O]MH8W70;DR73K2>:*W&T)F\.+K0F MOP1<:DU^.DU>&@1^!$V^2[W+[1#^=]V2"Z.9;G"HZ1J#DL(VDQ%[[ M\Z5F44NO6=D\:E3JC/;.L_P9_V)^>W1"R_7#>']MH R5Z%5$*TRH8[-;O[ M;.KHT^NN;.F3CU?)'B*=P:"J!@/(#DHCB=;^6Y SU6CK1EGK=SM]^PFVM MDI*(]B/CK;EJ\1$D5>R4"RP"92Y)"4 M+,K("IF(R+BK1$:#&\8]@CWA/5%#M=#YQF8^M>+A:2L>-N@:#,4E]>A'$\' MBP/.7DR T#8-+POF36GL6"K*WWR; M G^+@P#PBUW^X&<[(0$_3+OJ==@CGW"Z"IX!3PAY%!()N(XY=ERR05G )RXV M[,.G8]M O%3V\,.V?WPV!P8.%LQVX$LPMBRX9\RC%VSJ)SH0!L$"WVV2D8HW MK7@3[FGB>*9G.:8+[X4'1WCC/ [F/FX";Z#6@_2DD,4AMCHL0"*]N,.^Y, 1 MH)A!"4\]X"+@,9Y/D"9E6/>G%@#7C!F,/20.3_A]N=*G-IQY:5ZPRSE898 MZ>@?['CF1#-X;*A-,6V*G:$IUM.F6,-,L9Q,2>PQE.X/\'38)6@1YU"V6>JO M$FZ<"+!L[=544S#,WH$JD7H4-?/E\]^,]]@X%F3V!BL'D"%%"V MV$\8+0-L<>Y,' N>:X 18,=A%"RN0'"CVG7-!2AGCUFNX\$E+HM@ :XP#+#? M,?QO%KN1,W:"%>P$H&%RL M1=0;)FP:;A)@]WYMSFI3KPIVQ?H4%@;$G_ GP#'\"&< MB*86;I_,R?3)X@<6+D(PZD)8A#,A\\M\,1>BH?02)&$?+V8@33(KCLC6(_"D ME)S"*3'=WC[>T]\^^A?)9GQ8PX-L 9WB29SNV&4FS,.DN31*C\ 93 M=*5VH@4#4@JJ'A![@#P3VU[+UM4)*75:Q4[W &6 : @T79(HR8X-:NR-1GH" M2$&]R2<@I!*69R8:NX(EP$QE[\!H!IL+2=!@Y@0(-?\0QY,L).X&%LIQ"S(( M.C/9PJ1?,C?!U+>0S_(YH_,6!MTQ,Q\6WB*O$PY!2(Q_[J %(TH<]N6/*E^_" M-SAK%BM)03PP6XI)KALL?;P0[AE A?\[%G[;*K)!193(D2*J$!F6E$;F5W3Y M?(!1Y#P!OV7/">? NS8%%0"Y$7\2_#IAP*!FUJQ^!<(E 0+EPN8! ;!X>"VZ M3Z9E\7EN,RA=$L!GPF7!P,B9^B*G8C"PY:TI/ W[SSM2 0>"O(&!4NJWP;ES M_3D1-;SW*3!G19\2.]83'+B4Q-6@P]7#+OSD72 )X@G$0A?#$5$ AW'22O] M&3Q2[-SC@)40O>M$" *Z[)P>0DHKZ;=6"35027[\-"VXWB#8"?V@4 %0G)SW M%&HI3CV"CI_93G:],%CZ6G@E%S& *>R/N4@@8JC"!&P0X#4,NP#=P#IFCI>\ M:A)'J//G<#,0#*IZ&_04"H4TU"%7G.E%$5$"XK.+PA%NACW)TD3Z/K)>98A M%W!/ 4)$6O 3[-YB_-EWX[QP19L!Q8&7,<&DH!Q3E1WZ8(Q'TD9Y0B7K(5,( M"3-'\4$R.-J1\)IDE_\N)!B"JTW,])8$K3,CA.%_B_0MY"Q%TAP/Z.49^ *H M!9_C@V'NFB]A["1Q._XDE)'%.=K'H12K<&W($QH#LQ5H'*27)#:@L#$:[B#3 M.NRO*2]2-.AE,#6% 8ERV'1F9,BFC$-?&1AOPS :A37Q?@JZ.5/?M^E.>!)- M-H%;$X.;%*P(T\&*QT*WHL0VQ:44CI.64S'&F# %708FI0S8A3XJZ 4#R\)! MN6,7 2F?AR%'?(4,<69"')]6L*,2PS1]'ETB'IJ&+K/GB-DIPC?AV99PZ>() M^$E@R/)#"ETB$].#7YQ("--5 .ZP'/4#Q/)VEH>>$T E!I$;1":HSME'/SY_???CCG_#M[__W^=WG?[Y]]]-ST /1HTJ8#! M)$<<4IH-)=N]9[J+T"%K[&UJLSV (2YD-U[S2?I:<$D6K%LEH%1LA_TA4,T* MV] N^?#H_.6M'V!TZ>IWWZ?(T.<(])<,&+?')/L_/V;AE/0YNLC"8TAGN]E% M2C1SE(B1FLR#L K4&&34F'-_(O^)DQHF$Z!X?Y@"-S6 DIB9]'I\F3O.72D- M$# ZW)"_4%"5=#XL\']C,P I!B;2)TKCHO="UF>O>_6_[ =DM7[WM?B-/O1> M_XC>-=RZ:L^9=X01"!FK@._E"S"T! 8)VEA$-JXDF]QZQR:&#F)P61@EQ[U( M)'$G.-K.!6P)"PJ<2BN2,,L%#J4?!TY? B4"H?@V@R3 F]+\Z)22+2--:0;V MSE=X4<%T$CL,PW@VE^&I,$8C.LPO.P!#+J 8-+X0PR>>O)@6;3"?##3P_N#O M_.H-! :WS%"N%PQ%NA!%$^45, J1#Q1)S(,=1F^;L)"[(E@D=RV")B+3GSK< M[B*)X/CD4"91$3NS -<@Q2Q&+4-X4P!KP@B)'[0NF.%6\H^L8 BPDD)&LP(N MBRE2EA)T;D@>H!*#W+,P^P 6,T -B@"-<& MA,$#!"=AM KCQ9*7BJ27N#+H'LR!\K[A)UK5$BDRX%*9)'-1"Z!B YCV!@_AV]8;1[?/!)B/G MST&Z-HN?2W8>_G+ /SMBF"U_A@!XP+F1:/(_K22E("(ELC M@^Z!.:<+1/+XHQD M0!9Y#T\H!-.B?*/CX8TFH6I!_:G3+=+=A4!S1"+"H35 M%]'?DL;' 7 [!?,P\+;;O8-WLW"&&FKF@ZT5 MNYS=@RB'Q;(OB\!'%D_'2(-(K6 MEPRZSG@$)HCKA+,B:O!5TWB&=I:0\V%A_U7E3?U![VV_*ZA7Y,3AW:/K] %K M*J/DK)3AT8BFAZ'/@51R;O [^+J %,Z1>/5,V!WY81Q,&WA<;D MU'0G5RXHF#IDKO V$-E/6!C&@\/R$SKA4%CA;OD(5#E CINP 4KK96" MRA4!0J0O5\3D,.EH6=R5,<[$)EM7PX/&/YW5H C*M:P"V5ZSOTV#LR:LGN0G\#TQ];Q_OU?7LE=H[P'"EW#B@)\)T-%(P/.; .T/B*U/889$FJ^4. M_!)_+FN!#PQ!X#@,NA_X+8)[CZ3@P;4X-+4+(0O4-_C??N_0IO*#E'F'I;B< M0#WLB_S)-J=(FF7X3/PZ-DBS[-_?WE%(Q052HICE@:TW8(Z/!^?#I+3ZT&K: MK<-\*ANQ C\,K]+44(VW]9M$:VF(B.1D(?;2!D[-#JP881CN\&9 _AM(2A2;=CT.'LL#"IK""Y[\(0:!M*'.A)93 ,?Z.+0 M[.M_<_"[IT/'@"19'!YV1Y.MH-+'/GBLX)(?FB0PX@&T]Y4OPH-'HL69MF.1 M!;H.#C\T_(YALLB$_MDK]$%:K']HE704:0I<>B0&O6X=X(XD$QZ'-CRY-?6.86&(LN3#!]_1[NQV>Q\#/]^#9\59'LQV.9/% MYO; ^<*EWK#3O3G^49="O93<[@GKI;">.SD+7$#(!IJ/(P?;CZG<0O5**C=I M*]&5&A!,47FHQB',DG)$P3,;>'D990&SKN['KMI=*:LI<9HJ MOJ:FJ\@T=<@HI5A_ \YZ)9[&*L8@Y$KR9A)[EO2Y%.["4^>*&**4K!R@?41^A KK+\($)BJWU=@@B%0JFMTD2@LW86,9>;Q?4:T@^1Z/$O$T MD9+(W0[H2TO$ML-+.H6U3U',G)ECJ8DVM17A:3)5@!U9MJEN"0QBODE_E3=U M5&E80S$#)'[:I.5*U%9/*BDA",]/Q!Z5]:5)=(7[J7(-4Y-K[BF;L7^EIQO4 MT!P'^=I#I7WB 473FA[27I-\=24.:\ EX@@N'84*(Y..0RBY1Q,& I**/E^F M"Z;J*R0LJV95R-)+I8W'=$2D#D:5!>KQV+Q+!092/2.K.53)Y?DT/$JJ)L!IN* UEZN_Z%)<35=5#5')>7>B(L MZRI+%>T;^*Q"UM9T/57ID'Q^P)JCIK*.:%J$KO\B#M:C>N@SODRIS\U!S>DZLHQ,/QEH50(Z"!WIGR&?<35K(X:[ZIIQ5O*P8:D![&:K?%'D1P5 MS64U=0:2[JMH)[/:G-\4:*ZY4NK!K!JXR$5"5>\C+O<4M3TUW JY9\L&*]3W M0(G3G2?/5+0QZ%BPK<[E63,7-=LV;;#F+C;5-^RF06A@A2K>S/W(9^7LC>C: MKV;N4Y@05IRU/_MWS&7'+T6^W*1CESV'.;4.W\H/!RD[P0/W2M&9&JZG^?2$ MG1\5PT"R".:'\$?5].,N@7.N&!^+TDYG2M*@%DD%?.8KQN%V)L!C"9_[2EZY MFO@6CL94DT:U[#\P.(!"GY2"Q9A$0*-6C;!1K.-<'\4@D9J$I>Y9JB*VW%E M1?_7D*]HW;_XLI='7XY]48.+8AI!S&)50YCL6ZCHMN#4E63\2H^:!=8)I+]0 M\SA%LU:,KU4KV_@KWQ'TD*0IY?IAT2R'?[2LV7[O8,WV&Q/(J#)<3K^J7,E5 M]9F/#?3;S%U1-YE$;&^SJ>VKY4^XJ[D937'.(S76%796:_8&ID,6C&G/MJC\ M@[63R9):_M8@2PR8;<]^DO9L[=E1SM1LS9ZHC7A2W-::78$\KVX:M#$#T,S] MI)--VH.B0I5^6Y12FJMJRX8P$I-S7]NRK16=J\Z3D\AR=;%@N#U[$IF,UFPG M=VJB-7L2,UZ3)KO%7'9;Y(0LH7=@5\^.';=(4Z71PK9L"*.YK>$MU_&^;JEN MSV(_R6#!UE ;CC3A$\=K$"O)$=_]9S%K$2:MF^9SG;N:N MN6A1WL)D<^?9C[;T]UM@?J8N9L>_9#W>=:Y%\GG1?E_(HVA1,]<#];9)ZUKI3I:\M$0ZZA M:VLB'D^FX[4I3F!=-7IYH%L:O;[M0J]G00GB4&D;([ 6K$D<<6J+&&J5'](Z M1UZ>=FO-?E8,FSC/S:P8Z'>F 8GS5-_G23G4"(3:$;1&CXC&62TJO,6TU^II MU^=)=Y6'YENSN]95U-'D98.)CGEF");G?&I>A0LOMER.?0BVVN@YH.Y!"L3V M$&.AD6!K\&11T]OV<-C+U(Q:Z:B*/CVM4EY14#VB]$QW@V-JV[,=/* 4;6?- MGL5^A.7'VG>$]LNZ@??G*<.7NJJW!E78U;HUFYGC_($MJ>XL-F2IF*SGP$?M MM%A-SS98FXH]6U9=G,W[:!$?8<_UUF!H:4);6] D3;L6I5U!,M@MHCMP82W8 M4H!3[UM#=6V+*+?,C5TUHOX\=X/]DHLAX_;8==2^MS68:I5,,"<3;D4M.IPH M&^NG4:"EWJNNX_&KJ7C=BE:K:^:MJ'5>;>F(%].V'>61!V @D&%JSE0[&.-1 MDC5WE$LVL$G;W#4CT@\*[[*#^"D]KJL\"8V!(^%LOG&IHS"WIA[U]5*=&_J< M;Y2PU*:^S+W<=JPH[;,>IW452?NC4T0 M@X'BTOR /3O!IGM*[<91Y#H;IW_L/()(?6YR'*KC%&]Q.3.?5.=(JPZC=;XI M3LJU?7 9J0,OW.-[*$,W==9?%B4IARBQM8,7FF.77\VG&YO1%V]]F(+VVC0T M8FF5[Q<<=L8]/U:;[/([C[_RF6.JS9H FG]X_[N8M@PB'8=HJN%1D3'A90:E M#+K=WL? 5UNLX@ B&CN$>D -(NI#GT"I.A8ZRTKS%]1Y[!U.I/27/YC@-7(4*PZ\[[M@@BE- M,!@OU 6\;R^8XT6^*I%/33#GK*2AJ.)D55"4&Z<>+4MB(*8.2XA1290J4I7' MWC[>J]F+-J>Q6. $L0\!@,9CCV@)HMY0?+LJ_J@#H!G85_[DRMHX8*-_ JNH MMAI##?%.W63Y$U2MHI;_'&&5DZH.0SPKDS!+2$5QN!P57+AJ)CYPJ1EL,CO* M3A98YOBVYWH3( L>@_^>&1$]T"SFZ=][XQJ>3Y\"\&[$W]D]JZJ;7V\0;4@XUF= MP;A3)U"CC7_'( G5+&58GAAX]3D>_XLK>BA 3I,XBA4'7BG;'>93P#D"7DG2 M!MQ5G6$(^U&>W"99 SV!R =+44U7DII4%E'\&[?B.L-4Z^[N"(PO@Y[*L*@7 MT9-*4DT[O-2;"5>:AK9JP.<1H0VT4%-R6G[LJDFEN1^&SGB3[[3LL7%R>^$R M-186D_SZ-,#O>-J5>?R%D>%KSN>N+#=3"A2#/OKC\5XQ@'\D93F/@S!6-4,! MDI^Y^L3G47?TP_C''_H_*E*SJF1[RVVN&H]^Z_NVD?F\#WXXXQOGUBX]X]Z* M#";G4\^Y)4X7JJ@HQ7T&_-^Q$VRE/7>C+9KV\VRZ:C;P%^S3FXR >T'1PDS7 M]5\4@_&,QNUNG(-=RB^0ZZCH$7O,-B-3]47*8S?C,<@19OLSU=1$#Z(21:@R;S@PH6]=/L6-3-9HB%ZBBHI9DEZ+!P.-L+XZK M)J]#SK\J\ND\5@RVU)BW?6!GB80A'0$,I\JVVABM)DQ9*])N#0F7LY34_ 15 M^938=&&H^*H:9D4M(L]!0BG]]!'M,D53E?:D&*W?-2-\!,X%'(/M 8),+;"E MK)6S?)!2GCN-1ZKBRI>Y8]4<8UHOHX8T&C'\PA6Q)8%!Q;.[/ M8W<+.5"E[>KJ6O+50"I@8LGB:C;KNXEJU$!U)#RFDHY!_C7]02$WS59P[H[Z\ M*F^3K6_5I'3:75;%(D)&]*X2^4XS"L4NCU'X2C7I-G\"OSO8!K1ESSVI&=U4 MX;<419<#=I6V"()&V51"[PRDCYJXG_F*K .LO&529"E8Z"O:'<+M8[4SHZ*R M3\W\N@_KB(7-IM$>'*5/''T>)2)2QZUJ/$".=0!W(,_@_\LDOB@ MHE:/%$/L=8I7<)CTF'./!=SBSD9/8"D1J!K ^1@XST!+:H8OE5XI1R'KY"BH M7D@5@E@N:VT^VE!B_CHB7I7^_C"W$63+YJX71DX41QMS*R6>_W_<=*.I8L41 MB,!'CJF$&FG81S[AGJ)J1^)0A>-[QYJ:FPSLXNK^WF%O_6_P/V#*;3*:50[Z MULLD-_Z;,P-&<1?LN]&H (I XR26/YLYN-K M?.NK7(!:,*W%?*V83>,,_ $@RHW%RTNUD98CSEEMR(@N,=V<*WJ_ 7]VN%J& M$.P4FUN.LK 2B5H@3"R-4K6C49>Q4O''_EUN!Q3TIL*MI5-Q\4RUJ#=I&:9R M4^8K$H>:8\=5/!^$0^ QM**8G:IIXS"1U6)C,U2-D$]8@ZD_X!-7F7Y5W>XZ M!Q:1*G: FQJ.PDTEO3L6UZA#C,JB%//9L65M3$E7IQ$P>&K.>;RQ8J6R+B_4 MD;3]'Q#?FF1 &(5=:4B'<%SYJ:J-1V0-^S0-&X.VM!U M@0XCL-,X&6U.%&Y;XK?L@N$A&]:#RV-;,2DYR<6&L2;;=VW5V#N6A^!=&P^# M%54N^15JJPU%2;8:EB5(-UHZN]&&[SWYB%FKQBEW" M1Z7:'S0-CD'^)I,R99RX/HK)Z!U%D2I1[P6N2@"BT#J='-H,VJ7E*O*?P$0? M:_ A3MU$C;/7;Q_O MV=]C=\'Z?8/.&OWW?XWN7K-USZBH:LN RT2''(MSFR4A)I8036*MLJ7^R']ZHDC)6ZE1Q5OG4)#H<@^W@H>@B)X:/DN(Z1OPV]0/+T[B8'-!QG)6 ML,Z)C#HA@)H%#Q'HR?AIJJ9;=SNVHZ3>DK,TK)Z>.^()H^0@S@J7#1VT%5YC ME9LH_:XQV.NOB\>G5#VXNNX:=G'YF$B7-9NZV[BG@A]:GM^"&VS'?/)0Z.9?;J1_,6Z"UY?L M44PQQ ?B."/<:^XFH7]@\\2G205%81]_44D,H\-5Y$HE)TES#,>HSQ0S6FX2=(\O4NZ4Y5:,%"DC-&ACPJ!&H2J-;U7Q)3 M@&J& H9)=?F"P=(Z0D&(V5%.1@%WAFV&B7RD7$V3Y=5XD2MD0LH-\*7PWV%A MET7K0U HMTOLDM1.7'GF?_]7?W#W&M9$008D-N!J\XD7R=%TP?NN)K"T LYV MT'J.W8C(-7RA0U6 00-7"JP'W/;DF()LZ2Q\L@K<-57A/''8-3P=,ZES49N> MWUR;)&"N52/+M5]DJ-Y8OUEWJR,=EHC>6:I[&T M(1J33<[RI)'K=T9K7^Y+AMR0]@]+N"SK\R57G#;DRC\Z;;@EGI&AEU5 M-;#"*W.-IICP8%C:$8I5='DJZ7MZ9LQIZ+O7E_N9!LF& MY@#DJS&0V-3_;Q8H4<7JVR\171/E3%,%@XRVICHH\46^H-Q?+]GEC2Q&G) M2 \X'L&FV@!P9+ZRM$4$F_1%LW&CO4>ZC92Y3-CEC2P2B/ MML^9WR :% GW(?-O9',@)CK^L%(7G[R/DW;;VC2R'L?<6M2QU#&"E+@"L>+(_M3T+2\\.[K/D,#Y+SM.E,-\N=TTYVGD.OW&3AX'."O.SU^6/'^4W(8\5,5L!7>PG9>G-G M#P4&#1F=2-9G2>L2SYLK.$+#D?R+8[\R? MV:(0Q7VF40(>L31I;BK%>)'DP/0"426_C! MCR2K'5/PWN_\9<%^!<>9U,?C[[\* ^I][$8.J"7V>0&B;\;NH\"?3\5%[S^# MCI$'IN#^:7"'X40B*K M(B%"8*P)A)3"%A,'Q$]!D@J%F@MR9P?,$J!A2"&,02CA+#G0(G_WIQY[B#T/ M/DS!(H 5QR%!X^\/_S#$QVS-AC IS%C&DK.A= *P$Q^-! RX^!PH'M 'V 7% M(>#[$?R\MF18L-X,?D;; #Q84Y' &>GW@(@-@QZ5*US=QJG0B$G%5_XRI^ M;;JQ-]_F>/1C3SO;ST8J!)?"WCXEL@GEPF/.L&V3+"YLLI!\02$F'%/3 A4F M73^40$\>R50R:(+$ET!AZ*?4P"4U%(32RG M'4HZ*PX";G?8YLTDUZ)(C;-U+L?;"PZ3GPLW X1MLE5"NK)D;#KB'6@W_YS0 MI.T\)U0I(KPNGV B&WZBB!H;PU9Y\#^ONJ^8!6I,)KS3SW/T]N1G^1QQQQ50 MK&O.0_YS\L=K4$EV- 6R!*85;PCH7YN,K"?O?UX!1Z2/D1?WB?S!GXHX9=N1 M9E\"<_YJ%4?=;!NJW1M3U"SE_MM/D;UQ__W#[%V'J;-5H7/:?DX=,'K!\ <9F& M(WE(LM@/GDS/^8_LK, V_?[P'A]D6J:-\]EI]=BF 03G"2_"[,??X!$_Y M)=:*98931@T:KL9F*',H\ "9 !8/$^(&;]$BIUGXUR)'BYPCDYQ(6F1B1B25 M902'V4Z 27[*N+NN;Q5D$@6/I$'C!PN#38#]71F=@SO$HZDNI+-)U+0B;'F_ M''K<(GH7I$!./>AE9+QP61>#1F.2V[E*LDBBEX;(9F,USSQ?1R$O[K0J.BS/ MB!1B!T2MN9AHZ%L.$:LH6H^Q8AWS3N**RB6A3#9 M,RF2:[JA+Q%80G'E2BG2<25*M%93T 3@A(QUCVGAY+G$;$Q4+L(+TV+E:8.R1\LT. ,'N>PO.-<1Q$9B7,L8 M+6-.*F-D+SML#+9@$\?%DN9G- Z?9,O?K'3]!P)-]_6[/Q[IK][K'T54L:*V M/4RO_D.4?=/5^0/-6AXUD3JT/-+RZ*3R"%QQ<$?E0$N8XOL 27FO.+M9#\&%MB.\#YC14Q? M6Y5-I HMA[0<.KX@DJA<@UKZFH0WI)FQIBXXZKJ4_GUL&.LJBU M"Y,-E(NG";0P:B1I:&&DA=%)/:ZDF-%(NY90"5/DH-?$Q@X\)/C*1?"/!>($0NJ588<@K'- 6PFLK&JG+BL[G81\+0OFI9@3:0G+<&T!#N^YQ?Q8"8/CX@">^GD%=PS(ST'GO6) MRSI<+->(KWHD+ J$)$Y@F)L+(1_Q49Q:9FB9U$0*T3))RZ236E4RN48C-_'4 MB4EM?2.2.O!NF[.06P&/!!Y? ML?.@Z#2"%X6Z%UA3:4!+'2UU3E''Y('?%>,T50M[21%K%\_:A+GF4LLQ'C$K M..^X74KG+VN*T7Q13KJ0$ +SD"[%UD-"Z,HV_TEWF8K:L-7M]L6G42';%&71MU_2F^EWCS8FPE-W*T:FHF9@@$5@23#!3P ) NQ M?8_I"K$FQB+0U)J4Y.A6K,(52\I9TTP4I> @)-G JU"AF_29,G 5%,9('3 @@:(;06!#LM-938J([8>PQ9<-/CT2?!]Y4R])^XA:FEP.ZY^ M"GP%=^4O$?61$4[TC*8^3;>G\=O.QJ<;N99@N<9,"9$A1_Q'M%>V8VG?P)-H MW7*T]Q)BUC8!JSG.)R<\CCCGYC/8552U\)M $'A/C><^9FWJN%9NM^GW'[- MXGY+30'7]=1-A@B4.^I2R-Z<=1Z-BD*">B%@[=?QX\.Y;D M]G)3S0[[L/8N2\P_)!KG3Z9K).-I$JEOQL#1Q;AXW*J7/@7'"XH#%C:JE7%]?O,@:SQ],3L-M:*7](X) M.:Q:M'OEWZ0E@MXEA#"1"%/N_B@*3=M,5J*H)VUP#1IP&]Q4!B#+54-ODI?59A M%J5T6!*"\E."^GF5UC].@XI=XIMB63^;<>2_WA3KO%L9ZA3[S(*FIO7U*< 6 MU%<2\V_I_U[+!5QA7); D'SQB3#<[=R,S.EF-)/DQ76T1:_C%22-]:V*O1T)(KW/7/'2<7NM4 MH@:6@N+T?UY=OSH>FI*O?LV *D/Q-YV[#:R4:8Y+P=M;&0M6QHG"E>QT M.:QR!C+PMG-SJT6@J@C\7HO !J*E0?'>E?PF0\"7PRNGU4NK;3]451>.A88E M%T4-Q>7@Y(?8H\I];I],FZQF#UT5T0 D:!G5!"QL81YK7CDYEGK;Q7(V8DIS MF%8V%XD$K6R:@ 6M;,X 2S?;!ZBY=UZR*B.7;"Y71\?#V;??MP['" M87N ?V..R/T6X,FW@#]S+ZY=)'PP\% MG3&Z'34/-Q?&'4T54EHU:.*_1-4@TDR7K1MZ1F\X,(:C?O/0M\8W/:-X6#0//Q<&)LT\#B 5@^:[B\6#3H=!-KA>F#T;FKG@S2/:-UP MG@!OJE"Z,+IO*AIT/HAM%RZ1+IO*!IT+NC5+[?= M44?'E$Z-A::5FNES-Q>VOFVSPKXH6]<]V^-P;4N\CPU*G21IQ9<6L&< M$9ZZ6XW:2^.0'W?/9.GS:7O% MR#N<2L?#B/%O<^Z%W& >K]V]4%>X-$:;Z))+C2I](FU;Z^#&N.WI7L\^FFBFE..G#F;MW'8Y>S?N=R M],X?/&*N'Y[L,-IJ(^ "D='0TH]M2CS7(>\BG=;:0ZE/?H!M+ZALMX'1-ZX' MUT;OYN[$8G-[H7E1O'>RTE&MS;0V:R4N&ZC-MCLMIY791F4V[/>,VVNMRAJ) M':W*FH %K5;;>&&?WZOL*\_D%:_$%_3G M56Q1]4H!#"<"$K/V"FH%P/X&5T7L$W_F7LS9FFW=;=S6H',S^+XY)"-V%B0[ M T;QDFT5U_CJ%W@6BZ8<_A=PSF;PO&G(..S*9G^//2Y0/N@:K-_M]PR $C[L M%\>S FZ&<-%XP;[K&;WAP!B.^@P>-NKWOF>1C]\.K@=&=W C^HE^U^_=&:/; M$7,\>N$\<.#J!3<#9ODS8&RD:#;G\+7=85_@BN0E[,4,F1TXL!M\7?;N)[G- M$!YB39EI1,Z_TE>E6T9'N7'@<7Q M.[%!V)=E!L&"^5ZV++:$KH>)2]V=,5[\-(5\.NL887>>;'XIW1OGLT> >RN M/Y_!(EO%[85-VKE-RD/.>?I!=DW'FR.[WG9'@EW[QN"V;PP'@X1=@7E[-[NS MJPF2H--E !@722^]*L<-KAD)TA;;H&4#I<;PC1@@BH_H53X"X')5_9@2=ZV^ ME%8LW@K?PDX!_8!'?+[E>QZWB&E>G&A:*2\2COOXN,1TA26TAZG2(:^_Y8:\ MWA>&O+:*O[88:KN*U=+A)LAJ@\$HT8QR(J1D-3F1JR:K9?2*-TM=XT]R*T'* MM\QP"LCPK:_T4%@L-?=.%HXW?-?-F,S(W6X[ ; + GW[4\FCL6#E/A=QQR# MJHJ06\(8X&DESQJD#)OP&^R]BG_>??R 6W_D%I^->2 U<_9^ES\!T">#O$J9(]S^ !P--DC#!WB7:/T76A<^;#E0!)3[H4)P11D!%O'-V" MS=X0TV]S!PJ&K9X\V.:J[C87&5($@"XE?D_N:9&N0)DZ\5W7?R%92'(JY!'& M&0+I4>1E*DHS>)H7D8 $9U^:=.)C.I3EYU7Z] BA/QET%%L1(=O_>=5]Q2PP ME#$H"_M,/\MP+WTN+/1G,X[\US+@"\ARS7G(?T[^>,V2ZJFN;&59.GYQI+#T M"(S'N@?_5JJ170+3)?FV&Z6?9\8GR9/V-QQL/FBBM,F8@*6@)/V?5]>O&I"' MZ_<[&_H/9BKA4ACHK8R\@SJ7JGIK*[0%NW]33C&C,:&E M=]/1]C UO2=^+H;1LU++Q;!&+^08M&YN'E^;)1BWZM.AKE>C[X;M3 M'W#3DN\L)-]*?KHH%&B1=_Z(_>%[+?(:B)8&!6M7,IR(WUX.JS3T+*_03)?# M" U- UX.'_P0>V9L@RBV&SCB651&@#T+4Q?S1JGQM+==CZ*2M>- MUNF7AJ).JY8F($&K%JU:ML#2 P!M'#B7@)VVJ)0+0EGS5,EQ@%]O8LS!!@!6 M!;#V /;&G+ KM#MJWOA%KE8&=YUC<&-U@VGQD-3A936#9KZM6ZX3-W0 M-_HW=\;MH/8)![#]0XC.S2#'(Q!ZB5_CEJ]W"8$ MK.I^W[QDJ,X#M38#W1AN:"@:M+[&^<7&;6]H].\&C4//I7%) ^OYM3NG"?]B MT:#5 XY@'%X;_=N3#6'4/**5@Y9*ETSX#46#5@[D._2O;XUN=]@X]%P:EVCU MH.7211)^0]&@U<.K7VYN>QT=53HU%IIR#FCWKN-MPLH6TUM/E435O28;7VBP MH6O7,4\%-X:C&HJJXOG@G;#5:F/AAX'1[]X9H^'MB>5>LQKB-08_M1W,5JBC MQJ"AH5).*Z2S09562%LJI-N[6Z/;.UDMHU9'6ATU'@T-E7%:'9T-JK0ZVE(= M]8U!KV>,^EHA-1(_6B$U @VGE7*:19J.F\WJ1@D]K58Y_=%-IW9EAV:E;K?"]L7JI;G^TZ27U!(]KU-H95&HJG S3N;9\) M\,/(Z(\&QO5 'P X-2ITA:<67%K!G!&>M(+91L'<@7JY&UPW#GM:O9P< UJ] M:/6B\:35RR[J!3M;W!DW77T.X=2HT I&"ZZ+)/R&HD&?4'OURW $4&H<9C2# MZ$E51T7 .YPWQ\.(\6]S[H7<8!ZOW:GPW'H+MR*;I1NG-D)9Z\["A_3E>G?& M=?=DQ\,TBYRZTE$[<@T#^X41?D/1H'4#ZH:1,;BI'>33+*)UPYE"O*%"Z=(( MOZ%HT+I!Y( &H\:AYM(X1*L&+9,NDO ;B@:M&E[]TK_I:,5P:B0TY2S3F@:% MMA^/7<[ZGJS:/6^W/J\BTL-?O M\\MS(L"YM5>R5-CJ;W!5Q#[Q9^[%G.&65VSK;N.V!IV;P??-82^QLR#9&5"N MEVRKN,97O\"S6#3E+'2^L1D\;1HR#GNRV=]CCPMB&'0-UN_V>P9S/"O@9@B_ M_NTG?.@OXP7[KF_T;^Z,VT&7P:.&UZ/O6>3CMS=8W!31\> M0:^;!PY!FP"Q_!GR&Q,7F'+ZV.^P+7)&\B[V8(;,#!_;"X'79$I[D)D-X MB#5EIA4YSTZT8'8< ,/3BN6SX6)8$GS1[;#']%?8%:[D 2_Q%O_]7[?]WLWK MD$U\*P[II>'4F41T[XL9X%RW9].S\&8G"MG'*2Q"P.<=LUS'2XSG^25V5;AD?Y<6!Q_$YL M$/9EF4&P8+Z7+8N55@27HQS$!I=X"UZY GR=-7S0.R_^_I3NS;/9(T#=]>NE5.69PS4A0MM@&+1LH-89OQ#C%U8\ N%Q5/Z;$7*LOI16+ MM\*WL%- /^ 1GV_YGL,-WW4[HX3)\HK>=@)@ 5@2[MN?3!R+!RGQNXXY!DT5 M(;>$,<#32IYUDS)LPF^P]RK^ 3A&J*'F8'L[%KZ!DX(&<#QRB\_&/)#*.EN3 MRY_@C@GGH0$F/.IF\;?C/?,0UTKOQ)?CHH&+$2KX4+Q,+O"ZN$#\%58HVT## M!X"MF2S*DIHYX$^$=) BH8-[+:Q02BN/1QF*E@#+T-KR 0R!)+#<"Q,B*LB- M=LJ0M%/!&TE_;1(8RVT8ROIW,"*!<"OD@3@/+86!. "WL]J=.)XT54D4)*PY M#_C,B6=A8B*OM/M98O(7B)'EK53<7>!P>*R=T/(X1KYX\AP0$L@CR>+(6EV_ MBHD3A%%^+;!NLF]-L, #LE=37AOTC%0B5,J.XJ+?;89EU>)> (EDO@M8(9\ WSZ"X#0 5 M_(=H9<)M,H% H\(2K4@8Z&16AQVFOAYA4J%Q8#X]@7+%]Y"I,@]\BW.;D&?. MX=,W6%W$732JNIVA>%2J4_&]JJO-BXAWF7.,,D5(0"%]R'$L6"$Y&X8%IH-B M?6F%PU[.7<$G?-<;YLP->,&+'WQ%R6=)WJ,=H(S+WOPAL8/P ?C3NX\?#+3O MYNB0@)>WZ.Q&S,/.:-@@8KZ/*HDD#^VI:9<@YT_0D.SV7G\WO*$49_]Z8 #, MF&E9\2P6EJ?-02$Y9!8#^P,.)U')/N#9N!]?&:'1M"%/.LOP8:(7- MS04I"_EE$,,S4Y,_N[]GW%S?&7=W-ZL".[@!"K-P286)GC=G^"):'_@+L(X; MA !\%(&D[VYN^L80#$S03:;C(<4]FXY+:W*\;)U3[I*-@8_\L_,9+ 14OW&P M0&,6GG8/3.)FJGT=_=14:*>1]&]CC!:PMR#8D#8^<9#V "J.,&F3P/_B,YMD M7"+*T3S)R5#R4$3(ER0*F7>F2UX(V#PS'EAD+06^'5LHL?_BS/;I*4C.5H3V M:/(\>ES>FBL\6CZ#'A^RV(-_A7@%0@0:@P7ZXPAH%5TFY$(?B1#%Y#,Q+5T: MQA;HYW 2NR UL_4!^.C=QI4]J[E?J9!LJ&Y M^<2OQL"Q7Z_(Z/W9=%_,1?B*_:1&P(TAUS5IAQ.N"FC9=I"-!+V^I"SPU?-? M0.!RL ' 47 FJ'P<\ - ;3,?M$E _)(Q"IH5#C($QM,]^+W +7CHBH?B.? L[]6\1JMP"@P M4@8 <>N8/SF>V- R"XJ5RH=1<#0G.4SX)8S'_Y+@D FA9B+=1!Q.&KU$$;]S MPJ^ _\4UG'H1H_)I@ML)J MD-[&<0BV2@C$\AY>#/0#=#CQ7==_29Q^>A\G1P%V@]\4XVF-QA?8XXU>'UD) MC5XA"A 2G.CG-'JEJ7M(WF2(GF08^B ID3DE#W.T8@<@\?O41@PAZ6)] 4JDG@HFZ0^I0!I;O!C@S<-:GKA@R0& MP=AO]$([*?&TR//Z,_%J0,WF/"2@/M2?#NKCS($]XM2B,,87@4*DMB;2:^;PS7)V]"=SA:I-%QTNSC*,L1P!?+ M8147-3>YC0$'GC)DLC[A*C0)YG[$!=N!I!.A$)%LBT8\12WPTAE3X/$H>%(=&8D^1VPU?Y4Q]6!I92AB= VQR M?)#MA*M-]N#_;^]:FQ-'DNU?4?C.;G1O8(P @]U]>R)H&\^PZ[:]8._L_>00 M4F$T+216#]OLK[_YJ)+$RV\; ?6EVX >55E9F>=D5E4N40B?;AT!6%JN'ZJG MG^AZ'KL2PN0#YE,[C\A!P[6ZHFC(&&(N!/7YGE.!Z'$R/CT#A^'X< M9+A6Y1 )@.65@'KLH!9%K 2@V*>4TQL]FMS<[LD"DPSK$9[-AT10/C[F>C .G@[87!EN LT\'D^)YJ,GF$\@ MS(1L9)AF,624S9M2EBS\0BJ/38>GT6Q*PMS:R9FE=W(MI2LV;,S_8"=(P28$ M)8D_ET=,LX?,@!3V"%6"+O?-' HA88-5PVP%&2N9D2X;OP=W*2B2;N$!/S\# M+V0\3P&$I]^VZ&4.^/Y@#IL,K-L@S*!)V3@'J0P R: .I>]*DU9AW@:2L^#^ M6B$,PXW,7+@<)<>()"$\I)IY(Y7.(66F9XW30B/$F=$E9FO>TJ<13JG>2V') M)JGY;,YN/NEHY-*-BRV/3!86)MFW+"<)(( 2UQ("8*9YMKNR?^FS<(%Z#C]+ M0Q A?)Q>U(;J1BJ>K? 96MX 6S< @ P7PN-J#ZVK64O5P2$BX=**PW2JT<($ MGMHT@_L8BAV'@O4^S! N M&>_.4X,> RU%Z)T:*)PBP&E'XQQE46R!?!0XZKLPP+7:,@/"H-X1F&5@K#IK MVZ( Q(>Z!B 36PGV=O-4 2H!C-S/CG=12X8^%^4 M7!SW5DF&\^^XJY$W1'+(A'=5?MNI[!@VX#G<-PGO2#_+'9GT6>WQY'V8Q!7' MD?BB_OAJR+V:E8H\XOG!TT3EQ54:@OE-FPOW;.*H-I^:2'^S@7F&1CRRUWF^ M_]7WZ;M>1)#?)'M0K3:^YB+=2T9F334NGK8:8&%O0K3:8#? ]*?[G-@MRP^+ M"?!?_V?_\*N12H@V$\]M)=8615L4;5$VWJ+X">%(XB@V8(\'S0G9'(LV8H!I ML3$<#!!O#'0E$=JH%'&(M5'11N5C-6X<1)&+4UDN50N8C(9AHCAB,&5@HCAQ M>*7;U$[MJ"3#^;9PQS&G)<-;%S28DE2[F*2:J%]5FBHD:GHWA"LQ,RLP M 19P9C!*QF-/B &\+98_Y=/FE$E7-HB":)1B$@Y'X-4J@8>6Z&@;5$2-T#9(VZ"/ MU;B9+#!F(6DK5SZBOW3I0TK;:+E7@.%[, LNK5*\6WI;*350M#INRC[E) 92R/QLRN;YYBLWSR\_I_GE MG_(2H<<2@,'FEQ),R()E$L)#@$'CNUCP4>%N&>=Z\DEVH3 MIE1?TN[59#R&-LR>)[)X;P?;+GR1ME_%TB9MO[3]6A6I)5;J\X85/G:;-X'0 M+LO=7+IQ#X\.YTW+>2,5"WOH0[=NTDV23^&MZ[P2OX7+0/R;=#MR;EN*E>Y( MY@P(TWUZ1-]+M\;SV9]+SH):<&)>[J0SW@@Q?6B!;,WTD*I%OS/'VRQX(6V_ MF'M5V3A)0FP]'F-0FMEDP-M <,O&M"1F#D2CTR#P;)?YXPT"8R1$G/>7\O + MRFO+/1UA_OS'V9[P;LOI)FW.29A'N)WZA+93;]HFEMS1800F:+L;(JDAG<,R M&N%V-KEB@@\SGJC]PWPP921/-*$=Y[@%UT)-D#?0,>!X"C+M:\*CVD'7[[XL MD^+'!)!>@YRX65^L) Z^/H:B#I>"J \JQ=:HE \;<^78HL!S'8,O?* Y=)8 MYFNJL:T40ZRRLJ$J"'HX7Q#TB>/Q5M)?_4'Y"T<"FH+@[MM.8Z< ]29KC7)E MON#DU$AEI=X^9M:L?MQZ[KWQ(Z R$NWY4G8KKSKY$=4D"S(22XM):D]3^)'2 M7J= (Y%ZG6H1O([9*._GO Z*>*'+T6XI/[!XM()V/MMLTEXT4;3-TS9O;0<6 MSXS1-J^(@#N?'YJ7_=')2>7DZ!VFD03@;R[_PL0JST3,,<8DXB5_N27#Z:D8 M+YT2[S8L[*AP7>3^Q/<"@?8;T*,TZ_%&^(]I_F]Q\=IIR;IU.9W\++ M%V;X=!.XCBCLW63Y'5Y ??8#7>)@U+FC241\I29:>T-%H!$H>% M6*!7F.$J?L#WH=4G6V[PBC%4TX'?5PW71N.&NEFJ-&JE9O-PQ:;OZ79/SR_M MEK9P++1;VH"ATF[IB>M:Z\U2H_GBI:W:)ZT#R7W/+6=.D.#&[FKY#=U3\1.8 MR'-=W\9*Q<+XY C^ZS,NDT7Z6Z2]&N\X3FLW?8H2JGONYHNIP=M*G/'B)4_O M'0W_F*'<: Q2JY8.#FJE2KVV\ATV3S6:6S7WBK?_4/NTHAE#[=.T3],^+;?4 MUZP KW[Q2E_MT#YZ^>]C1S4N[_B;G92VZ(B[=3JT#TEQ[N"^*[EO]#S=-]I* MT[\;=:I?FO0>4+\?VB]+!_;A07V1>V^, CK:2SZ.ZI@%AOB?LP5SN = M]683FE;+785M2SSJ]D#P286_-"JEVJ&9N^CBXL(X#2P?&W3CW@I?5HG\I=HL M[>]#_RU#Q53H:_.@7JI7:UQX1(PM\$C+*[#!8]/03.X&V>Q\'1(KHL,7\0W- MYF')K#:FW@PW6[8=)F+AS:J"G.=R!2=7=K9:.RP=U)H+G@0&'MXVMB9T%")> MB]&:U;VX2L(%HU.>N7*BG5=,L59J-N;DU-SWH8FBC63\L+5+2A6H-.KU?.2CS M:,S_NU%GVE[DUD6=I.NBML,Q/K8F[(7.,5M943( QMK#W#S-YFYZ8BXUA 0[62QY3Y!*&T!7!*"HSOA)V1]XDEDU MQ']P9,@4@E=Q_0@>X/&0H $2THTG-X#]V#Z:)>I8V>BYJ+S8/>$[ZIQVU25X M%%A<*B,1CN!;D(@WD0:6GW#(HN'&@DF%[B8(M'PLW(KM@<'?I3^,O@7V=H/F M1 BBL4$V+8:D*.&+ -[N2A[6R\I @-R<&UDH 7YI1S$@@'C#X-3ET(T,QXWL M)(JHHCCA:\N;P+"KFAE9T270%:XZ0=IHA,1.%)4&O30_LS=H. Q M&UGESLE(]X609(+G)]&%T"'[3&4I;H#+AS W)OB+&*/WM[+A V &CQ]C*1!9 M,N,*]!^NZ>'KX%4P@:]ZQF^MU@7/5'Z5(DRRL,BB5JIB&4@'N=C[3X%5CZ4: MD*@ -8S&W'$J^F$-!E2'!-X#KPE":NR(V0\"$8X.X*UYCD_51;"," P$L+\D ME#"$>H@!@67W\9NPN(BR HO%#5;H3G@>_C_5M)1D@0P3(E&SRKWT ,9GSOT5 M54,]>&4UU.63NC!3N)C5GARN_)UIF\N%UK"42-DXQUIOV4P"?9^R&6"4XB D M0XT:&KH"C0&75:+2/P',2 Z989'Q()2S[PZMB><*L"KX3 P1!#ZYW 2TD?F' M[89V,H+) 8^,2K*!J2%CNX2]HU_(_1$&@,F//?@S\PG](.'I9P-^G."/MY;' MX8Q MY7K*Y"*](ANYS.++:GMHE!C+Z9S:]17DVP>K4:( 12:?6S3[Y\*";T!K1W?A0_#5?I4Z6XZ0I_L40H[$7 M3(38Y8F4P8P2EQ@#:41 P,&LPS=]0'<#%T$*# *TB1XU'>3>9>J6C^0" MG#"$(O394#XBVE24;"OSU%^5Z9+QV.]'/_!!EFTY8N3::6]!JB %HH%NG&1,7<;C,0_#?66-0!(K M"P=.C0-\WQ=I^F*I.,B^IB&2$,M]P1W9D[#] [!R+ODNUB]YN6%Y).S8O575 MZ?!]W#A5VQ!3!UEM5'9JF1*PDY7J EH6(F0F. W&WI[2&-)U8.9!2%6C2^CO M\ZA9YLU0)IL57FU%I(-9U;; E@E-YB^4H%E,K13X(?5PJ):N=$ L9$JPI!(& MD&$0/F,ZA(;@\5F$+T@G'4E?C2J\':-./SF:(.W&+E9G1/>IX@F9):4@AFS> M=-)G:2MR065$-&#@V#+2S-U%J4V,2(2WH(LJ+!U&TLU/J.FI$9#VC"/7./T? MFC0J<28Q3P[<3#%@8IF14$U(H8^L)DD-EN.8VHHH3ARETKD,G'J$>J2L18G5 M0J<0"5I&T*7,E#\Z@ILU68Y(+F@JGJ(T/#OL .3W7]0#.Y_E,"6 : MV30]FF'*EA%8I(L M"JY5.@.N!^DD2*;*H\(/J>9+G W-1>9RBV4GF>5,TS]2>BS"RCP')95$.3FI MAJ7\*0X"0/;08P1"\#=0! H<^1-VW'8"Z"(5[WE>;'D+YHBQ('TN43[;0A*2 MP$22I- 6[I@-,&BS-U'&,PG1DF:MHQYEQE!-Z503I_Q_SFD]:*[*QG&2,A!P MMC(DE J-U (T$@<;61[\/ F2E 7?N9Y'BD *S!5E4WXVI;59C5D.$BGEL^XL M?B4N!)3E9//UUC/Z*U5 \DMIW/ ]&1)"?[#E\9 M[%K!>L3GO7*.\+Y_U1##=;[M="[;/ZYKU_^\:IU==BY;EYU_M?'#J?K[N-,[ M.CWO7>W\V@%(8-3*QC\3> H0<4+)J/CPA:<^'Z=AWLAHT3SZ884_16QTW>CG M1BVK0L]F1/"W1[->F4R;DW(I5F42DN%5:0;S\?!0W%@A>9[_S(KV/SG1CEB0 MX2."?$V0Y2-UKGY]='YVV3T_[5U?=,^/VL=7W79/:EF];%"*-Y"F]0(I@H-* M]3H56M3QU13L:6- -4W49+-F6;\W"M->I1'K*!DC/$CS<8Z[MC*D[3E%#*WVB&"AX&(T8U&")'Y"(;DLN',_PS*(*5$D0%*QD5/J%I,OH-O9-4VJ?+"6CE M\5#>?/53R\5AF"P)0@AK0)%W\-%)?^3&R_I$346*C/A;TG_\D\NY$W/A)*Q, MY4GVBL]!O)J6;9?4.VM)KWV4QJG#Q), ''L2E61X$/I&<:]\!]V(P.\HX9 > M@_;1*$&(%W._EZL?K<1X0/VRWQ>H(,:Z, N@<+@#'8H(3&=.(15_-J3(C/S) MLH'%A1_(A0 4&4-X-J5'TX'.%!E%#C@[=4F!#RW()98(?*?KS&SHPZWJ,#XM MI+@EM< (^G_RS*''9X(R?(&#RZL+K?'80Y+JQED6@:BCM(7RV4@4=V7HE/,5 M*)"A.Z;(0A!%+C9N2=_+QG?%>6FL16IG2R\U%!P=A/?)+ \]]XFS_PZ30:E9 MP:2VM5C"GJ#X,$UV6N:C5F[.DX< MI+/V@Q4S/+,E+E'ABP="'&]/Q3]\;*O75V?=]F^=WF6[VSZ^[K5.V[WK]C^O M.I?_=PU&+T %N&61KWBC?+ MR(F][HK2\8T?UB3% MDB=-QD L)HUDKUPX81#:V0A>+*-=]JTPF=^17X/B)B M7$2N"+^X%Z$M-Q;AH@&*?!&WX]L"N=:+;@"MC$- %KA"ENG)+Y5R[0")(;]Z M:K1:0'\((479R! PEVW&1V*DDL=4,OP,*N7&L\49 /.P5J/%5=:(,%*)%R1X M+D'Y-,T"7>(5:@AXB.TB4^_)GM<_69\_53\SI0=,!<_>@!E5NSYNG[2N3B][ MUU<7YV:XM^K!K)YH MY/@4,#H;2QXE]FVGLF/8PO-PIRVPY_2S/(:,/JN#S?CP,3OP/&LV/@]!CFV8=;"I(3I*E7- M.*9]ZI1/T(CDK=7M$5"R%=H&?SQ9L5Z,3;9-L8:TN34BID[J^KZL0(?2OOE_:V4S M=W[0TZG4ULS,I5'9]Y' 3"\?$LA;:I%E#$,Q^+8SC./QE[V]N[N[V=ROF/7#/5!^TZS4&_N'5?A<,9N5O7A4K=0. MZ_6&8UZ+^]JN61[&HQD]I98YN!.)5C5\H35?G@OMV_FUQ4N[: E?5]"!&(YQ M),*8CDO@0PFSL(K<$];Q$>G\Q+-'<6V_-19)[-I1":\LTXJQ41#%M/_>CW$A M?.XEH7I)MEWD#^'X(G*L20G8GRU&?1$:U1H?))W.%FNZ3RO4W_+S9W#C/8SB M^DQAIIV;';T]V/W',R'9%BN$I(N;K1'DZY]% ;=9(Q9)8-,T MSW;NVPT6QH M2_$<2['Q>F%6]ZJ'>PQW-.MZ#]95U:Q+LZ[W8UW5MV!=WR>>=1=]%+\Z8'Y5 MSA,L36@TH=&$1A.:I81F6>5B36@TH=&60A,:36C>C]" XJQ?[DCSCE?RCL.: M6=VOPO]FT]S?ECJ@,X8Q*M"$0D1TW]0B;4X8PWKF3/0\%;#VXT4UO-7P=I-'4L/;-X>W-<"J M?RL&OBV,'#5V3K&S^S/>%?)IK' MO)+'5#6/T3SF$1Y3O6Z^'8^9K_.G>%')63, ^.JW"L?E5/*8=;V*X_RDL-*0_,2S4LT MVM"\1/,2S4L*(Q-M*30OT;SD!;RDJGF)YB6/\9+J]<%')5@T+RF:@FM>HM&& MYB6:EVA>HBV%YB6:E[P3+S$K9KESUM-DI(ADI##RZ/A(,(Q_?^^>&AT_BBTL M5GH87F-Z;2DTIM>8?N68OG?T>S$P_3/DI7'W0[C[ MTKH/_& T,=KWL?#IX%(\871D:2"N@;AVKQJ(:R"N@;BV%!J(:R!>)"!^U#K5 M0'SM1_P1('YD>7;B\:J;4]?_V<(2C%1ENC@K0K:]&+T&?.NXM_@9_E.MY@9C"[@[=*71#T)'A-]V*CN&+3P/H(?M M^C?IY['E..JS? [?@0C(L\:1^*+^^&HHD56DP)Z '^OE?3 H=T,W%KOX;O2V M=Z$U7J@D*,QJ)LR<7?X"F;Y9 Y^EWHB1'&,H0H%PJ)QVB;1< MZ_CVZOA&*7D2^FXT?(:B/]UI3GF7O[S4MWS0*]]:2U(:A+7FJ"PQ%G./T=#R/+@[AE\-1X@1?!\'^.&O_W-0K0*11&M$?YM?#7B[,4[" M<1!!EX)!=C3_@3IT?[K(<6@$\&5XYT;"B)+^GW Y/ATO]%RK[WIN/.$[K=B( M^&$E[(ML5Y380^!^LD>S+71].X"VA!8RR?[$",4 = D/ @4Z:/GXQ8T;Q5R5 M (82KL/T4=HLPY$))8,ZN;AJL^S';-]*T"Q;C&-DL+D^QM06^7IJ/3P:I%[^ M0(U:@1)O]RN7(F)\I;G8]!;'8%1KLC_#4'5H;-V(W7XHK)^[U@#Z\\7R[JQ) MM&/L%5;4SVN$%%\_\)QGB_Z%ORJMON[?R:_;U$A9^H/;5R ML[92!%8H?6(67ZME/=*< 0U _+^YL\ M!!T?D?I/7*MU"6;7&HLD=NVH9'1\N_R4%.O(=1Q/:*NDK9(6^[N*O5:NS*6R MM-C?W\HTRO7WR+X56.[+3/V[#\*479=NOA^;)6=GW&@CV!GH@OD^^%-5E/#0X2G(? MD*Y9NULR+H;EXR>QC14.JF8;FFU\M-A7 M1Z[?B6W,A?)?-PX;INLSC@/%NO5>XX?KQ8%/SD*$O@BELS"TMRBNV=+>8LO$ MKKU%42)3[[?4EZ7GQO!P^TTGQ'/VJ0Q=,3#:]\).:(/*^6#@VB)\@R4':R2$ M3Q>AZ]ONV/+F)?%Y.U,V+\SK%VHZ:]>U2:Y+BUVG571:I9 CH],JA1T:G58I MR$#HM,K:#%6:5OG[>:]]\;MQTFU=7K:ZYZ>=0C@?'2(KV#3::IZA$RK;&"+3 M"97<4/T]B,1X:)R$5AQ;(4A#NXGBVBOM)K9,[-I-%"48M=E)!,ZDG+B^Y=NN MY6U])F5.$K35/ON]9=N@BC&HST.IEB(=@+#F6YSK+-Y^X$Q(LL-XY,$?_P]0 M2P,$% @ ZH$04UVT!*C8#0 FX4 ! !I:W0M,C R,3 V,S N>'-D M[5U9;^,X$GY?8/\#UP^+'NSXRAUO9P;I' ,#Z=C;\1S[-* EVB9"2QJ22N)_ MOT7JL&3=BMVMQBH/W;985:SB5RQ6493\\>>W-4,OA MJ6U>=86_00<0R;)-: MRZN.*[I8&)1V?O[I[W_[^(]N%]W>CQ_1M2'I"[FEPF"V<#GY\/3Y!_3'IR\/ MZ,E8D35&M[;AKHDE41>MI'1&_?[KZVO/7%!+V,R5T)7H&?:ZC[K=0/ -)U@U MH%LL"=)_(W0T.!IV!Q?=X=EL>#XZN1R=GO,9+@L:W$4)L7!Y=G)\,R/G9RRV+,$8VZ)Y:V#(H9N@IL/1'-+:,'KIF M#'U1; )](8+P%V+V?*EOPAP);^0 #4N,+)#GKJ\ZD<%[FW/6L_FR;TK>EQN' M](&H"U2$4Z/C\YF$ADR:01"CM[1?^M#0!TT'W<&P>SP,R$OT$9,^S#,);D@" M>L-V+A?CS7U\/+RLJ];0X5BYMOKXE M"^PRZ,JU_G(QHPM*3 B,C*BH%B.(-$O,ET0^XC41#C9(%3TA J0-' SSL/_' MYP_EZI W2^NJ$YU> MX;?*"J5-TIH:!%;*/],7YO>J\UY= MJNF10"8,D_I356P20;;>:##.^Y@;W&8$%E1#WKTY#%M8VGH:51H811Z3U25; M8??P_3TZ:J$664(&:]92+"I@#XK(]RA1/]QMLQ;O8W>;P)3RFF364U.1(/%3 M'ZJZ[F[26!H,+261)?8)DT*GK\5Z9*:8>]-!02PJ:N(Q'48?G=)7U2=9!]1U MDZ ,T9^ZVX*DG*/L%C$U1R5:('@CXU^I,BYI5<8^]:GL. '/P32J[#JIE6I$ M(VQ9MM1JZ&O!5<>AUL+V+\%%E8B.E&DS$(8HI.\SLH:51)('7>>HIE^_C,L4 M 5[$C;-7*\!"M0+%3+*@%M5&#-0?ZD;W9(*ND.KK8W^78U>8*X@YL7[2GQU. M! C1XQ/A]DGR. W,#)?58-QJELWG7PWPV($I&*QF^%Y5;N! MA;!LDQ]442O]F6O=YX6@8Q-_C_VC+O M+-!M,X:UA*^U7AV]>'P!\C]+D>?%^F%*L \_8LM$GC@4D5' M_ST ^02:Z[V_&]LRB06]?\),;8<]K0B1(H)A$641?$,%7R@$J=L-OASD"T*> MI!:X/0 WQ1S:5D12&*#R*,;9BB ]*@LI^A 3_$,+<3V(PRMBLIC .J0MRY^D M&2Q%T!YG0[N5B.P%VLIL07T_J$_2-IY7-C,)%W=_N;"DJ8S.H+(TQMD2BB _ M*0MYM(M_8L<6_T9>3^B#WU<[P??@"S=8K.Z9_5I^?F\YBK ^+8NU$HFTS!;2 M4HEQ>';D$4OX=[+XY IJ$1%%,8>H"+@SG02'_/#%$Z&P"H2T2%5#ZH%"]#(A M?D%9\HM-K25,!H-P*Q6Q3.(BY,X3R(6B= 6CA2%?6@MA-0@_84$A $;+8L#G MB2XM"@L2AHK3T/>988BG-H,EBJ3/QSIRBH"_2 "O>U$S-E;&*R>(](2V7:&@ MK]8MJKG%D^LXWM$6S*)U3L8N126^(M@O$[!'I<8+I';?XAWKK"T)U*T;/%=[ M76EK;)2@ +7A(+F^*G;D\[?@5)R D5(A6-]+L+3+5D('58$VEWI.":@Q*9%44$2NSBLNC+T(NN<$2D:9K MM)B\%LJ#%^K[+MC+%N[#Y(Y-[<(=?0@^M5OC^Z_A9ZHT2_>/\MQ%WI#1R0(0 MX2XQ[][4"DY4#3^1*\)O](.Y\H'B.654G<'.<;Z#=ECDBLGMN9*U0A<%2BFW M]=5"@5[:=;5FR%<-171K?7,/A4;EQ;$T$O#:%>&536!.][@]Z3B1+PITEOK&WOUC7M7';6;V/J6 M2>6KB\!K/2+D:XQ\E9&T4:BE+KM [>[V2EMJO>]L4N5@5XJQR(^2V\V!V#:< M[3^#CM\1" -(Y*T/DX7:H3,@*-Q2YL*TV^&Y=AQUCSU:G," ,Q3*AG$3[ M:W5>Y'+);>Z4.QRQH!5]*X9ZJ$-]NK+^) MNS>#N28Q[[F]COG6UW+H ZI1Y-K)_?8BU_:418&V: 'J[OI[PLN=4-9UZ^6' M\O+(V<;*2W-9WB)_2FZ:1\],_G^OT!_[N^_J\J_$W^FEW^CEO\Q70T6?Y9^0 MN:JG>&\@O769NLUU3]1-?/4FL:M.1J/W AG]-N81S#(88+X92[)6*G60<.=" M4JG? OX+MUTG(*5 TD'>9YBWU#9G6I#IV0T9K2*)TKV#/G>IX9_G_26+ @' MZK&*L9A-W3FD"Y,%7-1G5H0,#:[ T)AQ* 8XZYS.C+S)3PP<.3"_!*%GMO=S M#2,97/\ZAN>8N$T/)HO,8TF^O,#::CQ1O.$:D!S8:.][CLW!'D4"QI2&AL*6 M?A+(O^_$B'IUB:U^086:NDT?P]DD['VOE(8.3HUC*/I$9&)\]B"HH4/TN\V? MU63%#I7J=6:^_^]&.]=C=C"[MYLU>4XMN(5,*830S[6JQ-]@(_ M)F\K;3\:[^2D*>U-B6OE,_'TVC+=X +:[\_XL24)I"@9YB9:OR,#Q^":7%%# M"K:F[GI;$5OF$S%8VI]ZX@6.^XY>8P; MF='80#-FK_9L9;L"6R8 ,'N%MHW2/FY/$57C#7N$Q5$28A69ED;70./NZ4*N M(%ZJ-S2:29LRFQMHRLW=)&G SL4&JAT>E?2/\,?USVIMH"$PU-F.E-'80#,@ MV$*>:#Q/.>AIZ*J?VTN.USO %)$UTS1N,Y906>W4)B$K2]U 0V_)7$)Z '3Z M-R@A,0C.0*M?S UKP0*J:!JU_"]DE)]M2ZZ^^<[%%"H+M5FUA$+FT548!/?L M9_9OF+EP65D6PEB6W,<10'0\ED99JKP.'- @Q!1Z$\I4]SC_$_RBJ.^LL2WY MVNS-&XF=>RDSPK=%?7K;5Z_\/@)W+ &+:2+>:(./-\K.M%FYKW+V&:*J3I&?"T$3"%]WU9KJO;_0U\,"\^:W T\[NNFIP4L^!:'NC"TUY:?-EL3/&*Y? M,3>CGB_&UE3KJ[^IA.(>4ZX7W' _\N#]-&4CJ'C,;Q@6,%_\^X\3KH.)-]'" M\)E'TL"Y%4X+PG<6@K26!BX!J0-^]P8I$15JU]'SNUQX4J@;B)0_GV;VU.7& M"F9;$+YUX(YC5XZV@6B&M_;+6%F2^%N:Z9U6]'X,]:?_ 5!+ P04 " #J M@1!3:[SC^6T)

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end